

ARTICLE OPEN



Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020

Konrad Pesudovs¹✉, Van Charles Lansingh^{2,3,4}, John H. Kempen^{5,6,7}, Ian Tapply⁸, Arthur G. Fernandes⁹, Maria V. Cicinelli¹⁰, Alessandro Arrigo¹¹, Nicolas Leveziel¹², Paul Svitil Briant¹³, Theo Vos¹³, Serge Resnikoff^{1,14}, Hugh R. Taylor¹⁵, Tabassom Sedighi¹⁶, Seth Flaxman¹⁷, Jaimie Steinmetz^{9,517}, Rupert Bourne^{4,12,517}, Vision Loss Expert Group of the Global Burden of Disease Study* and the GBD 2019 Blindness and Vision Impairment Collaborators*

© The Author(s) 2024

BACKGROUND: To estimate global and regional trends from 2000 to 2020 of the number of persons visually impaired by cataract and their proportion of the total number of vision-impaired individuals.

METHODS: A systematic review and meta-analysis of published population studies and gray literature from 2000 to 2020 was carried out to estimate global and regional trends. We developed prevalence estimates based on modeled distance visual impairment and blindness due to cataract, producing location-, year-, age-, and sex-specific estimates of moderate to severe vision impairment (MSVI presenting visual acuity $<6/18$, $\geq 3/60$) and blindness (presenting visual acuity $<3/60$). Estimates are age-standardized using the GBD standard population.

RESULTS: In 2020, among overall (all ages) 43.3 million blind and 295 million with MSVI, 17.0 million (39.6%) people were blind and 83.5 million (28.3%) had MSVI due to cataract blind 60% female, MSVI 59% female. From 1990 to 2020, the count of persons blind (MSVI) due to cataract increased by 29.7%(93.1%) whereas the age-standardized global prevalence of cataract-related blindness improved by -27.5% and MSVI increased by 7.2% . The contribution of cataract to the age-standardized prevalence of blindness exceeded the global figure only in South Asia (62.9%) and Southeast Asia and Oceania (47.9%).

CONCLUSIONS: The number of people blind and with MSVI due to cataract has risen over the past 30 years, despite a decrease in the age-standardized prevalence of cataract. This indicates that cataract treatment programs have been beneficial, but population growth and aging have outpaced their impact. Growing numbers of cataract blind indicate that more, better-directed, resources are needed to increase global capacity for cataract surgery.

Eye; <https://doi.org/10.1038/s41433-024-02961-1>

INTRODUCTION

For 2020, the Global Burden of Disease (GBD) Study reported that cataract remained the leading cause of blindness, with approximately 15.2 million cases [95% Uncertainty Interval (UI): 12.7–18.0] that comprised 45% of global blindness [1]. Cataract also remained the second leading cause of moderate and severe vision impairment (MSVI), with 78.8 million (95% UI: 67.2–91.4) people, which comprised 39% of global MSVI. In spite of global advocacy efforts, such as the VISION 2020 Right to Sight program undertaken by the World Health Organization and International Agency of the Prevention Blindness, and an increase in cataract surgical rates (the number of cataract surgeries per million

population) reported across the world, the progress made against cataract has revealed substantial inequality and inequity, with lower-to-middle income countries (LMICs) shouldering the greater burden and having poorer visual outcomes than high-income countries [2–4].

The majority of cataracts are age-related nuclear cataracts, which typically cause vision loss in the sixth decade or later [5–7]. Cataracts, part of the spectrum of diabetic eye disease, are also increasing due to a global epidemic of diabetes, with diabetics more likely to develop cataracts and more quickly lose their vision to cataract compared to people without diabetes [5, 8, 9].

¹University of New South Wales, Sydney, NSW, Australia. ²Department of Research, Instituto Mexicano de Oftalmología, Queretaro, Mexico. ³Chief Medical Office, Help Me See, Jersey City, NJ, USA. ⁴Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. ⁵Department of Ophthalmology, Massachusetts Eye and Ear and Harvard Medical School Schepens Eye Research Institute, Boston, MA, USA. ⁶MCM Eye Unit, MyungSung Christian Medical Center (MCM) Multispecialty Hospital and MyungSung Medical School, Addis Ababa, Ethiopia. ⁷Department of Ophthalmology, Faculty of Medicine, Addis Ababa University, Addis Ababa, Ethiopia. ⁸Department of Ophthalmology, Cambridge University Hospitals, Cambridge, UK. ⁹Universidade Federal de Sao Paulo, Sao Paulo, São Paulo, Brazil. ¹⁰Department of Ophthalmology, San Raffaele Scientific Institute, Milano, Italy. ¹¹IRCCS San Raffaele Scientific Institute, Vita-Salute University, via Olgettina 60, 20123 Milan, Italy. ¹²Ophthalmology Department, CHU de Poitiers, Poitiers, France. ¹³Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. ¹⁴Brien Holden Vision Institute, Sydney, NSW, Australia. ¹⁵Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. ¹⁶Vision and Eye Research Unit, Postgraduate Medical Institute, Anglia Ruskin University, Cambridge, UK. ¹⁷Department of Computer Science, University of Oxford, Oxford, UK. ⁵¹⁷These authors contributed equally: Jaimie Steinmetz, Rupert Bourne. *Lists of authors and their affiliations appear at the end of the paper. ✉email: k.pesudovs@unsw.edu.au

Surgery is the only treatment for cataract, during which an artificial intraocular lens replaces the damaged lens. Cataract surgery is extremely efficacious in terms of restoring sight, and multiple studies have demonstrated its cost-effectiveness, which appears to increase over time [10–12]. In 2015, the International Council of Ophthalmology estimated that globally, there were 14 ophthalmologists performing cataract surgery per million population, but that ranges from less than 1 cataract surgeon per million in low-income countries to as high as 32 in high-income countries, further revealing the global inequity in access to eye care [13]. Age-related cataract exposes another persistent inequity in universal eye health coverage—men are 1.7 times more likely to undergo cataract surgery than women, and even in high-income countries, women are more likely to wait longer for surgery and experience poorer outcomes [14]. This gender inequity is partially due to the fact that women live longer than men, although sociocultural barriers are also at play. Based on the 2015 GBD Vision Loss Expert Group data, if women had the same access to cataract surgery as men, the blindness burden of cataract could decrease by 11%. However, women, in fact, need more access to surgery than men, to address the gender inequity [14]. Gender differences in cataract burden for 2020 have yet to be analyzed.

With the publication of 2020 GBD vision loss data, there is a need to explore further the global and regional trends in cataract burden since 1990 and better understand the regional and gender inequities of cataract burden. The objective of this article is to provide updated estimates of the global burden of vision loss due to cataract, disaggregated by sex and region, for the period from 2000 to 2020 covered by Global Vision 2020. This is done using the best available ophthalmic epidemiological database, the Global Vision Database which is a comprehensive, continuously updated, online database of ophthalmic epidemiological data curated by the Vision Loss Expert Group (VLEG) [15–17]. Additionally, we assess progress against the goals set out in ‘Towards universal eye health: global action plan 2014–2019 of the World 60 Health Assembly (2013) [18]. This Global Action Plan set a target to reduce the prevalence of avoidable blindness by 25% from 2010 to 2019.

METHODS

The VLEG have maintained, and progressively updated a systematic review of population-based studies of vision impairment and blindness published between Jan 1, 1980, and Oct 1, 2018, including gray literature sources. Data from this systematic review were combined with data from the repository of Rapid Assessment of Avoidable Blindness (RAAB) studies, and data contributed by the GBD obtained from the US National Health and Nutrition Examination survey and the WHO Study on Global Ageing and Adult Health. Detailed methods are published elsewhere [17, 19], and briefly described herein.

In total, the systematic review identified 137 studies, and the VLEG extracted data from 70 studies in 2010, and a further 67 studies in 2014–18 [16]. Studies were primarily national and subnational cross-sectional surveys. The VLEG commissioned the preparation of 5-year age-disaggregated data from the RAAB repository [20]. Studies were included if they met these criteria: population-representative and visual acuity measured using a test chart that could be mapped to Snellen fractions. Studies using self-reported vision loss were excluded. We used the International Classification of Diseases 11th edition criteria for vision loss, as recommended by the WHO, which categorizes people according to presenting better-eye visual acuity. The classification defines moderate vision loss as better eye visual acuity of 6/60 or better but worse than 6/18, severe vision loss as a visual acuity of 3/60 or better but worse than 6/60, and blindness as visual acuity of worse than 3/60 or less than 10° visual field around central fixation.

Data were stratified into datasets including so-called vision-loss envelopes (as per Flaxman et al. [16]) for all-cause mild, moderate, and severe vision loss, and blindness. Data were input into a mixed-effects meta-regression tool developed by the Institute for Health Metrics and Evaluation (IHME) called MR-BRT (meta regression; Bayesian; regularized; trimmed) [21]. Presenting vision impairment defined each level of severity.

Prevalence data for under-corrected refractive error were extracted where available, and otherwise calculated by subtracting best-corrected vision impairment from presenting vision impairment for each level of severity in studies that reported both measures for a given location, sex, age group, and year. Other causes were quantified as part of the best-corrected estimates of vision impairment at each level of severity. Minimum age for inclusion of data was defined as 20 years for cataract.

We generated location, year, age, and sex-specific estimates of MSVI and blindness using Disease Modeling Meta-Regression (Dismod-MR) 2.1; [19] the data processing steps are described elsewhere [17]. In brief, Dismod-MR 2.1 models were run for all vision impairment strata (moderate, severe, blindness) regardless of cause and, separately, for MSVI and blindness for each modeled cause of vision impairment. Then, models of MSVI due to cataract were split into moderate and severe estimates using the ratio of overall prevalence in the all-cause moderate presenting vision impairment and severe presenting vision impairment models. Next, prevalence estimates for cataract were stratified by severity were scaled to the models of all-cause prevalence by severity. This produced final estimates by age, sex, year, and location for cataract vision impairment stratified by severity. We age-standardized our estimates using the GBD standard population [22]. Data on blindness and MSVI due to AMD were presented by seven super-regions (Southeast Asia/East Asia/Oceania, Central Europe/Eastern Europe/Central Asia, High-income, Latin America and Caribbean, North Africa and Middle East, South Asia, and Sub-Saharan Africa) and globally. Data on other causes of vision impairment and blindness will be presented in separate publications.

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

RESULTS

In 2020, 17.01 million (all ages, 95% uncertainty interval (UI) 14.40–19.93) people were blind due to cataract (Table 1). This breaks down by gender as 6.78 million (95% UI 5.73–7.98) men and 10.22 million (95% UI 8.76–11.96) women blind from cataract (Table 2). The majority of these are over 50 years of age with 15.17 million (95% UI 12.70–18.00) so affected (Table 1). Of these, 5.96 million (95% UI 4.98–7.11) men and 9.22 million (95% UI 7.73–10.88) women are blind from cataract (Table 2).

Overall, 83.48 million (95% UI 71.76–96.98) people are estimated to have MSVI from cataract (Table 1). Of these 34.59 million (95% UI 29.69–39.95) are men, and 48.89 million (95% UI 42.05–56.06) are women (Table 3). Again, the majority are over 50 years of age, 78.79 million (95% UI 67.20–91.40) people, 32.41 million (95% UI 27.55–37.74) men and 46.38 million (95% UI 39.66–53.66) women suffer from MSVI due to cataract (Tables 1 and 3).

Cataract caused 39.55% (95% UI: 33.48, 46.34%) of all blindness in 2020 worldwide. Regionally, the highest proportion of cataract-related blindness was found in South Asia (53.20 [95% UI: 45.00, 62.11%]) and Southeast Asia, East Asia, and Oceania (41.82% [95% UI: 35.30, 49.38]) (Table 1). The regions with the lowest proportion of all cataract-related blindness of all blind individuals were High Income Countries (16.82% [UI: 13.66, 20.60]), and Central Europe, Eastern Europe, and Central Asia (20.53% [95% UI: 16.50, 25.15]). Cataract caused 28.30% (95% UI: 24.32, 32.54) of all cases with MSVI in 2020 worldwide. Southeast Asia, East Asia, and Oceania (34.00 (29.32–39.00)% [95% UI: 29.32, 39.00]), and South Asia (29.87% [95% UI: 25.64, 34.83]) were regions with the highest percentage of cataract-related MSVI of all visually impaired individuals (Table 1).

In 2020, the global age-standardized prevalence of cataract-related blindness in those aged ≥ 50 years was 0.84% (95% UI: 0.70, 0.99) and for cataract-related MSVI was 1.01% (95% UI: 0.87, 1.15) (Table 1). The variation of crude prevalence with age is shown in Fig. 1. The regions with the highest age-standardized prevalence of cataract-related blindness were South Asia (2.23% [95% UI: 1.89, 2.61]) and Sub-Saharan Africa (1.49% [95% UI: 1.24,

Table 1. Number of people (mean [95% UI]) with blindness (presenting visual acuity <3/60) or MSVI (presenting visual acuity <6/18, $\geq 3/60$) due to Cataract, the age-standardized prevalence (%) in people of all ages and aged ≥ 50 years (mean [95% UI]), and the percentage of all blindness or MSVI attributed to Cataract (95% UI) in world regions in 2020.

World Region	2020, total population ('000 s)	Blindness due to Cataract in 2020			MSVI due to Cataract in 2020			Percentage of Cataract MSVI in 2020 (≥ 50 years)
		Number of people ('000 s) with blindness in 2020 (all ages)	Age-standardized prevalence of Cataract blindness in 2020 (aged ≥ 50 years)	Percentage of all Cataract blindness in 2020 (≥ 50 years)	Number of people ('000 s) with MSVI in 2020 (all ages)	Age-standardized prevalence of Cataract MSVI in people ≥ 50 years aged in 2020		
Global	7,890,000	17,005 (14,395–19,926)	0.84 (0.70–0.99)	39.55 (33.48–46.34)	83,475(71,758–95,983)	4.34 (3.71–5.02)	28.30 (24.32–32.54)	
Southeast Asia, East Asia, and Oceania	2,192,710	6305 (5322–7445)	0.97 (0.81–1.15)	41.82 (35.30–49.38)	28,238 (24,354–32,390)	4.71 (4.04–5.41)	34.00 (29.32–39.00)	
Central Europe, Eastern Europe, and Central Asia	417,291	291 (234–356)	0.19 (0.15–0.23)	20.53 (16.50–25.15)	3172(2620–3733)	2.13 (1.75–2.52)	17.64 (14.57–20.76)	
High-income	1,087,856	505(410–619)	0.09 (0.07–0.11)	16.82 (13.66–20.60)	8214 (6955–9574)	1.46 (1.22–1.71)	26.44 (22.39–30.82)	
Latin America and Caribbean	601,551	1101 (910–1320)	0.78 (0.64–0.95)	30.11 (24.90–36.10)	4658 (3935–5391)	3.39 (2.85–3.96)	19.03 (16.07–22.02)	
North Africa and Middle East	631,727	844 (676–1037)	0.91 (0.71–1.14)	27.31 (21.88–33.57)	5399 (4573–6303)	5.81 (4.92–6.80)	24.73 (20.94–28.87)	
South Asia	1,841,435	6352 (5373–74169)	2.23 (1.89–2.61)	53.20 (45.00–62.11)	28,744 (24,674–33,511)	9.46 (8.11–10.93)	29.87 (25.64–34.83)	
Sub-Saharan Africa	1,114,806	1604 (1358–1857)	1.49 (1.24–1.78)	31.56 (26.71–36.53)	5047 (4342–5781)	5.14 (4.40–5.93)	24.69 (21.24–28.28)	

Table 2. Number of males and females with blindness (presenting visual acuity <3/60), and the age-standardized prevalence (% [95% UI]) of blindness due to Cataract (all ages and people aged ≥50 years) in 2020.

World Region	Total number of Cataract blindness and aged-standardized Cataract blindness in 2020 (all ages)				Total number of Cataract blindness and aged-standardized Cataract blindness in people aged 50+ years in 2020				
	Total Population (‘000 s)	Number of males(‘000 s) with Cataract blindness in 2020	Number of females (‘000 s) with Cataract blindness in 2020	Age standardized prevalence of blindness in males in 2020	Age standardized prevalence of blindness in females in 2020	Number of males(‘000 s) with Cataract blindness in 2020	Number of females(‘000 s) (50+ years) with Cataract blindness in 2020	Age standardized prevalence of blindness in males in 2020	Age standardized prevalence of blindness in females in 2020
Global	7,890,000	6781 (5733–7978)	10,224 (8671–11,956)	0.18 (0.15–0.21)	0.23 (0.19–0.27)	5957 (4978–7110)	9217 (7728–10,884)	0.73 (0.61–0.87)	0.93 (0.78–1.09)
Southeast Asia, East Asia, and Oceania	2,192,710	2297 (1929–2722)	4007 (3394–4714)	0.18 (0.16–0.22)	0.29 (0.24–0.34)	1966 (1626–2360)	3577 (2990–4235)	0.73 (0.61–0.88)	1.16 (0.97–1.38)
Central Europe, Eastern Europe, and Central Asia	417,291	102(81–124)	188 (152–232)	0.04 (0.04–0.05)	0.05 (0.04–0.06)	88 (70–111)	177 (142–220)	0.17 (0.14–0.22)	0.20 (0.16–0.24)
High-income	1,087,856	221(178–267)	284 (231–351)	0.02 (0.02–0.03)	0.02 (0.02–0.03)	196 (157–241)	260 (209–325)	0.09 (0.07–0.11)	0.08 (0.07–0.11)
Latin America and Caribbean	601,551	483 (397–579)	617 (512–738)	0.18 (0.15–0.22)	0.19 (0.16–0.23)	433 (353–529)	571 (469–691)	0.76 (0.62–0.93)	0.80 (0.66–0.97)
North Africa and Middle East	631,727	314 (249–389)	529 (424–648)	0.16 (0.13–0.20)	0.26 (0.21–0.32)	276 (214–350)	478 (378–595)	0.69 (0.54–0.86)	1.11 (0.88–1.37)
South Asia	1,841,435	2706 (2293–3166)	3646 (3087–4262)	0.45 (0.38–0.52)	0.57 (0.48–0.66)	2497 (2096–2939)	3414 (2883–4026)	1.95 (1.65–2.27)	2.48 (2.10–2.90)
Sub-Saharan Africa	1,114,806	655 (555–762)	949 (801–1097)	0.33 (0.27–0.38)	0.40 (0.34–0.47)	498 (415–605)	737 (615–885)	1.32 (1.09–1.59)	1.63 (1.36–1.94)

Table 3. Number of males and females with Cataract MSVI, and the age-standardized prevalence (% [95% uncertainty intervals (UIs)]) of Cataract MSVI (all ages and people aged ≥ 50 years) in 2020.

World Region	Total population (’000 s)	Total number of Cataract MSVI (all ages)	Number of males(’000 s) with Cataract MSVI in 2020	Number of females (’000 s) with Cataract MSVI in 2020	Age standardized prevalence of MSVI in males in 2020	Age standardized prevalence of MSVI in females in 2020	Total number of Cataract MSVI in 2020	Number of males(’000 s) (50+ years) with Cataract MSVI in 2020	Number of females(’000 s) (50+ years) with Cataract MSVI in 2020	Age standardized prevalence of MSVI in males in 2020	Age standardized prevalence of MSVI in females in 2020
Global	7,890,000	34,585 (29,694–39,953)	48,889 (42,051–56,064)	46,375 (39,663–53,662)	0.92 (0.79–1.05)	1.08 (0.93–1.24)	32,410 (27,550–37,744)	32,410 (27,550–37,744)	46,375 (39,663–53,662)	3.96 (3.38–4.59)	4.67 (3.99–5.40)
Southeast Asia, East Asia, and Oceania	2,192,710	11,351 (9749–13,032)	16,887 (14,577–19,432)	16,164 (13,880–18,651)	0.94 (0.81–1.07)	1.20 (1.04–1.37)	10,676 (9,096–12,387)	10,676 (9,096–12,387)	16,164 (13,880–18,651)	4.06 (3.47–4.67)	5.24 (4.51–6.00)
Central Europe, Eastern Europe, and Central Asia	417,291	978 (805–1157)	2194 (1806–2599)	2123 (1740–2524)	0.42 (0.35–0.49)	0.53 (0.44–0.63)	922(750–1101)	922(750–1101)	2123 (1740–2524)	1.80 (1.48–2.13)	2.31 (1.90–2.74)
High-income	1,087,856	2985(2525–3485)	5228 (4431–6107)	5071 (4278–5945)	0.31 (0.26–0.36)	0.38 (0.32–0.43)	2811 (2349–3306)	2811 (2349–3306)	5071 (4278–5945)	1.27 (1.06–1.48)	1.59 (1.34–1.87)
Latin America and Caribbean	601,551	2057 (1739–2390)	2600 (2202–3008)	2434 (2045–2847)	0.78 (0.66–0.91)	0.79 (0.67–0.92)	1915 (1599–2242)	1915 (1599–2242)	2434 (2045–2847)	3.38 (2.83–3.95)	3.40 (2.86–3.99)
North Africa and Middle East	631,727	2405 (2034–2811)	2993 (2539–3482)	2795 (2354–3288)	1.22 (1.03–1.43)	1.43 (1.22–1.67)	2229(1868–2644)	2229(1868–2644)	2795 (2354–3288)	5.35 (4.52–6.30)	6.27 (5.29–7.32)
South Asia	1,841,435	12,732 (10,878–14,943)	16,011 (13,766–18,590)	15,187 (12,989–17,698)	1.98 (1.71–2.30)	2.32 (2.00–2.67)	12,017 (10,208–14,116)	12,017 (10,208–14,116)	15,187 (12,989–17,698)	8.71 (7.46–10.12)	10.19 (8.74–11.74)
Sub-Saharan Africa	1,1148,06	2073 (1780–2398)	2973 (2565–3392)	2599 (2219–3020)	1.10 (0.95–1.27)	1.29 (1.11–1.47)	1837 (1562–2147)	1837 (1562–2147)	2599 (2219–3020)	4.76 (4.08–5.52)	5.47 (4.69–6.29)




Fig. 1 Crude prevalence of Blindness and MSVI due to cataract in 2020 globally by age.

1.78]). The lowest age-standardized prevalence of cataract blindness in 2020 was in the regions of High Income Countries (0.09% [95% UI: 0.07, 0.11]) and Central Europe, Eastern Europe, and Central Asia (0.19% [95% UI: 0.15, 0.23]). The regions with the highest age-standardized prevalence of cataract-related MSVI in 2020 were South Asia (2.15% [95% UI: 1.85, 2.49]), and North Africa and the Middle East (1.33% [95% UI: 1.13, 1.55]). The lowest figures were found in high-income countries (0.35% [95% UI: 0.30, 0.40]) and Central Europe, Eastern Europe, and Central Asia (0.49% [95% UI: 0.41, 0.58]) (Table 1). The variation in these results by gender across the regions are shown in Tables 2 and 3.

Between 2000 and 2020, the global percentage change in age-standardized prevalence of cataract-related blindness among adults ≥ 50 years decreased by 27.54% (95% UI: -27.68, -27.39), among males by -31.78% (95% UI -31.91, -31.64) and by 24.82% in females (95% UI: -24.97, -24.68) (Table 4). However, the absolute number of cases (unadjusted for age) increased by 29.72% (95% UI: 29.46, 29.98), in males 25.65% (95% CI 25.39, 25.92) and in females 32.49% (95% CI: 32.23, 32.75). An especially large reduction in the age-standardized prevalence of cataract-related blindness amongst adults aged ≥ 50 years (both sexes) was found in Southeast Asia, East Asia and Oceania (-42.99% [95% UI: -43.10, -42.88]), North Africa and Middle East (-39.97% [95% UI: -40.13, -39.81]) and South Asia (-36.53% [95% UI: -36.65, -36.41]), with a modest reduction in high-income countries (-6.86% [95% UI: -7.10, -6.62]) (Table 4). The greatest percentage increases in absolute number of cases were in Latin America and the Caribbean 71.25% (95% UI 70.86, 71.64) and in high income countries 49.30 (95% UI 48.92, 49.69). Only Central Europe, Eastern Europe, and Central Asia showed a reduction in the caseload (-4.40% [95% UI -4.66, -4.14]).

Between 2000 and 2020, the global percentage change in age-standardized prevalence of cataract MSVI among adults (≥ 50 years) increased (7.17% [95% UI: 6.98, 7.36]), among males (4.70% [95% UI 4.52, 4.89]) and females (8.94% [95% UI: 8.75, 9.13]) (Table 5). However, the absolute number of cases increased by 93.11% (95% UI: 92.75, 93.46), in males 93.69% (95% CI 93.32, 94.05) and in females 92.70% (95% CI: 92.36, 93.04). Sub-Saharan Africa (2.29% [95%UI 2.12, 2.47]) and Southeast Asia, East Asia and Oceania 1.96% [95%UI 1.78, 2.13]) were the only world regions where a substantial increase in the age-standardized prevalence

of cataract MSVI was observed with notable decreases in South Asia (-5.53 [95% UI: -5.69, -5.37]) and Latin America and Caribbean (-4.83% [95% UI: -5.01, -4.65]). The increase in the absolute number of cataract MSVI cases was greatest in Southeast Asia, East Asia, and Oceania (115.21% [95%UI 114.83, 115.58]), and least in Central Europe, Eastern Europe, and Central Asia (38.18% [95% UI 37.87, 38.49]) (Table 5).

DISCUSSION

Cataract, the world's leading cause of blindness, remains one of the greatest opportunities in global health to make impactful and cost-effective contributions. Cataract surgery is safe and highly effective with both higher and lower technology approaches (e.g., phacoemulsification or extracapsular techniques respectively), and can be provided relatively inexpensively [23]. As a surgical condition, it requires a system able to provide one-at-a-time clinical care, like most causes of blindness and visual impairment. There are various eye service delivery models that can be used to address the cataract burden. However, it makes sense to combine it in a system with other ophthalmic services, ethically addressing other issues that will come to the attention of the service as well as providing a more professional-friendly work environment to retain capable eye care professionals (ophthalmologists, optometrists, eye nurses and others).

As an endemic condition, the ideal approach to the problem is to develop sufficient capacity and health system functionality to make ophthalmic surgery widely available worldwide. Given the relatively low level of infrastructure and consumables required for quality surgery, government health systems are well positioned to address this issue for the economically poorest persons. While funding limitations may constrain their systems' scale [24], cataract surgery has considerable economic and quality of life benefits compared to its cost [10], which can offset the investment. Moreover, several health systems in different locations have demonstrated that self-sustaining services can be provided at costs most patients are willing to pay while also generating surpluses to provide service to the very poor [25, 26]. Such "cross-subsidizing" systems have made a large contribution to alleviating cataract blindness in much of the world, although these require a dominant service provider e.g. Aravind Eye Care

Table 4. Percentage change in crude prevalence of Cataract blindness (presenting visual acuity <3/60) in adults age 50 years and older between 2000 and 2020 by world super region.

World Region	Crude Prevalence			Number of Cases ('000 s)			Age standardized prevalence		
	Male (%; 95% UI)	Female (%; 95% UI)	Both (%; 95% UI)	Male (%; 95% UI)	Female (%; 95% UI)	Both (%; 95% UI)	Male (%; 95% UI)	Female (%; 95% UI)	Both (%; 95% UI)
Global	-28.75 (-28.90-28.61)	-24.58 (-24.73-24.43)	-26.30 (-26.45-26.15)	25.65 (25.39-25.92)	32.49 (32.23-32.75)	29.72 (29.46-29.98)	-31.78 (-31.91-31.64)	-24.82 (-24.97-24.68)	-27.54 (-27.68-27.39)
High-income	7.88 (7.61-8.16)	2.58 (2.30-2.85)	4.51 (4.24-4.78)	58.76 (58.36-59.16)	42.88 (42.50-43.26)	49.30 (48.92-49.69)	-6.69 (-6.93-6.46)	-7.16 (-7.40-6.91)	-6.86 (-7.10-6.62)
Central Europe, Eastern Europe, and Central Asia	-19.82 (-20.04-19.60)	-25.74 (-25.94-25.55)	-24.23 (-24.44-24.02)	4.00 (3.72-4.29)	-8.13 (-8.38-7.89)	-4.40 (-4.66-4.14)	-26.60 (-26.79-26.41)	-31.03 (-31.21-30.85)	-30.14 (-30.33-29.96)
Latin America and Caribbean	-19.70 (-19.89-19.51)	-10.77 (-10.97-10.57)	-14.83 (-15.02-14.64)	58.24 (57.87-58.62)	82.64 (82.23-83.05)	71.25 (70.86-71.64)	-23.99 (-24.16-23.81)	-18.39 (-18.57-18.20)	-20.83 (-21.01-20.66)
North Africa and Middle East	-45.07 (-45.23-44.92)	-39.04 (-39.20-38.88)	-41.39 (-41.55-41.23)	14.12 (13.80-14.44)	26.84 (26.51-27.18)	21.87 (21.54-22.19)	-41.99 (-42.15-41.83)	-39.64 (-39.80-39.49)	-39.97 (-40.13-39.81)
South Asia	-30.68 (-30.81-30.54)	-32.04 (-32.17-31.90)	-31.10 (-31.23-30.96)	30.83 (30.57-31.09)	37.40 (37.13-37.67)	34.55 (34.28-34.81)	-34.95 (-35.06-34.83)	-38.63 (-38.74-38.52)	-36.53 (-36.65-36.41)
Southeast Asia, East Asia, and Oceania	-41.72 (-41.84-41.59)	-38.94 (-39.06-38.82)	-39.73 (-39.85-39.61)	15.24 (14.99-15.49)	24.55 (24.30-24.80)	21.08 (20.83-21.33)	-46.86 (-46.97-46.75)	-40.55 (-40.67-40.44)	-42.99 (-43.10-42.88)
Sub-Saharan Africa	-29.68 (-29.84-29.52)	-28.83 (-28.98-28.68)	-28.74 (-28.90-28.59)	24.41 (24.13-24.68)	38.07 (37.77-38.36)	32.21 (31.92-32.50)	-25.87 (-26.03-25.71)	-24.19 (-24.34-24.03)	-24.93 (-25.08-24.77)

Table 5. Percentage change in crude prevalence of Cataract MSVI (presenting visual acuity <6/18, ≥3/60) and in adults aged 50 years and older between 2000 and 2020 by world super region.

World Region	Crude prevalence			Number of cases ('000 s)			Age standardized prevalence		
	Male (%; 95% UI)	Female (%; 95% UI)	Both (%; 95% UI)	Male (%; 95% UI)	Female (%; 95% UI)	Both (%; 95% UI)	Male (%; 95% UI)	Female (%; 95% UI)	Both (%; 95% UI)
Global	9.82 (9.61–10.03)	9.70 (9.50–9.89)	9.72 (9.52–9.92)	93.69 (93.32–94.05)	92.70 (92.36–93.04)	93.11 (92.75–93.46)	4.70 (4.52–4.89)	8.94 (8.75–9.13)	7.17 (6.98–7.36)
High-income	20.98 (20.74–21.23)	9.66 (9.44–9.88)	12.62 (12.40–12.84)	78.04 (77.67–78.40)	52.75 (52.45–53.05)	60.90 (60.58–61.21)	1.56 (1.36–1.76)	0.02 (–0.18–0.21)	–0.48 (–0.67––0.28)
Central Europe, Eastern Europe, and Central Asia	12.39 (12.13–12.66)	9.21 (8.96–9.46)	9.52 (9.27–9.77)	45.79 (45.45–46.13)	35.12 (34.81–35.42)	38.18 (37.87–38.49)	0.96 (0.74–1.17)	1.33 (1.11–1.55)	0.46 (0.24–0.68)
Latin America and Caribbean	–0.64 (–0.83––0.44)	2.41 (2.22–2.61)	1.11 (0.91–1.31)	95.81 (95.42–96.19)	109.62 (109.21–110.02)	103.30 (102.91–103.70)	–5.59 (–5.77––5.41)	–4.22 (–4.40––4.04)	–4.83 (–5.01––4.65)
North Africa and Middle East	–6.92 (–7.11––6.73)	–3.43 (–3.62––3.24)	–5.00 (–5.19––4.81)	93.39 (92.99–93.78)	100.96 (100.57–101.35)	97.53 (97.14–97.92)	–1.03 (–1.22––0.84)	–2.89 (–3.07––2.71)	–1.92 (–2.10––1.73)
South Asia	0.83 (0.64–1.02)	–3.41 (–3.59––3.23)	–1.14 (–1.33––0.96)	90.29 (89.93–90.65)	95.27 (94.91–95.63)	93.04 (92.68–93.40)	–3.46 (–3.63––3.29)	–7.64 (–7.80––7.48)	–5.53 (–5.69––5.37)
Southeast Asia, East Asia, and Oceania	8.65 (8.45–8.85)	5.62 (5.43–5.80)	7.12 (6.93–7.31)	114.84 (114.44–115.24)	115.45 (115.07–115.83)	115.21 (114.83–115.58)	–0.70 (–0.87––0.53)	3.53 (3.36–3.70)	1.96 (1.78–2.13)
Sub-Saharan Africa	–6.04 (–6.22––5.87)	–0.15 (–0.33–0.03)	–2.29 (–2.47––2.11)	66.22 (65.91–66.53)	93.70 (93.35–94.04)	81.29 (80.96–81.62)	–0.60 (–0.78––0.43)	4.70 (4.52–4.88)	2.29 (2.12–2.47)

System in South India. Systems for eye care should contemplate the value of “patient financial contribution” for cataract surgery as much as possible; offering universal free or highly subsidized surgery may unnecessarily leave that health care financing resource at the table. In addition, surgical campaigns have been used extensively to deal with “backlogs” in cataract blindness; these are ideal for unreached/remote areas where development is unlikely to reach the cataract blind on a reasonable time scale without interfering with the ultimate solution of local capacity development. Our data demonstrate that these sorts of efforts have been fruitful in reducing the per capita levels of cataract blindness over the last 20 years over much of the world. Indeed, the World Health Assembly Global Action Plan target of a 25% reduction from 2010 to 2019 in avoidable vision impairment (WHA 66.3 24/5/2013) was met for cataract blindness (from an age-adjusted prevalence perspective) [18].

However, the successes have not kept pace with the impact of population growth and aging, with the result that the number of cataract blind is substantially increasing. Cataract also remains the leading cause of blindness despite these improvements and its favorable treatability. Thus, further investment in sustainable health systems able to provide quality cataract surgeries is likely to provide very substantial societal and economic net benefits. Because development is a long-term proposition, sustained commitment will be needed, whether through committed funders (e.g., government or charity programs) or self-sustaining organizations (private non-profit or social enterprise systems, or government systems allowing cost recovery).

While our data demonstrate a notable improvement in blindness (worse than 20/400 visual acuity), we did not see a similar decrease in MSVI (worse than 20/60 to 20/400) which also is associated with substantial disability/economic impact [27, 28]. Indeed, MSVI became more prevalent and nearly doubled in the number of cases. This pattern suggests successful targeting of the most severely impaired cases, albeit at the neglect of the less severely impaired. However, MSVI also needs to be targeted to alleviate visual disability and its socioeconomic impacts [27, 28]. Indeed, research into willingness to pay for cataract surgery suggests that people in the MSVI range (e.g., younger people otherwise capable of employment) may be more willing to pay for cataract surgery than more severe “blind” persons [26]. Expansion of the indications for cataract surgery may be needed to accomplish improvements in cataract MSVI also [29].

The WHO criteria score blindness and visual impairment based on the vision in the better eye. Following this logic, it would seem sensible in an economically constrained environment to focus on operating one eye. However, second eye surgeries also have important benefits to vision, visual ability and well-being [30, 31], and has been shown to have very high cost-effectiveness (cost per quality-adjusted life year gained) and a favorable cost-effectiveness in an evidence-based review [32, 33]. In addition, second eye surgery provides insurance that vision could continue in the event something happened to the first eye for persons in locations with poor service access. Binocular vision is important for activities requiring depth perception, falls prevention, increases contrast sensitivity and provides better binocular visual acuity than single eye surgery alone [31]. Because case finding of second eye cataracts and second eye operations have less marginal cost for bilateral cases than first eye cataracts [34], it is desirable to operate second eyes as well. Persons also may be more willing to pay for a cataract surgery after seeing the result of first eye cataract surgery [33]. Second eye cataract surgeries generally should be made available to patients in cataract programs, especially if patients are willing to pay some or all of the cost.

While improvements in cataract blindness were observed over the last 20 years, huge disparities in the prevalence remain between low- and high-income regions. South Asia has the

highest number of cataract blind and by far the highest prevalence, a significant focus in this super region has the greatest potential for improvement. However, other poor regions (e.g., Sub-Saharan Africa) which are expected to see a growth in the elderly population in coming years and have a very high prevalence of cataract blindness amongst the elderly needing aggressive efforts to develop an eye care system capable of handling the volume of cataract surgery and other eye care services which can be forecast to be needed. Given the very low number of ophthalmologists and other eye care professionals in these areas, the time is now to strengthen and expand both training and systems for eye care delivery [34].

Our results demonstrated again that women are disproportionately represented amongst the cataract blind and visually impaired, and that the inequity is widening. The extent of this difference varies across the globe, but is generally consistent. The difference might reflect differences in family willingness to pay for male and female surgery [35]. Differences in acceptance of surgery between males and females could be another explanation. However, acceptance of clinical services tends to be higher among women than men in high income settings. Notably, female survival is generally longer than male survival which might be associated with a higher burden of age-related cataract even if service utilization were equal. Baruwu et al found that five years’ access to free cataract screening and low-cost high quality cataract surgery was associated with equalization in willingness to pay for cataract surgery across males and females [36]. Improving cataract surgery quality, community knowledge of the benefits of cataract surgery, and reducing barriers to surgical access likely are among the core strategies that need to be implemented in order to overcome the male-female gap in cataract surgery utilization. Without foregoing the promotion of cataract surgery among males, who also need to increase cataract surgery utilization, female surgery promoters and other strategies to increase female use of cataract surgery also could be helpful to reduce the disproportionately higher female cataract blindness and visual impairment burden.

The impact of the COVID-19 pandemic on cataract blindness is unclear at this time. Emerging evidence that service delivery was adversely affected during the emergency phase of the pandemic may drive the cataract burden up [37]. This may be offset by global decreases in life expectancy from the disease and its sequelae [37]. These impacts may not be visible for several years, but are likely to be overwhelmed by existing trajectories of population growth and ageing.

In summary, as the population grows and ages while coverage of cataract surgery remains incomplete, immense numbers of people remain blind and vision impaired from cataract. These numbers are expected to continue growing markedly as the population increases and ages worldwide, especially in the least developed countries with young but rapidly aging populations and high cataract blindness/MSVI prevalence. While much has been achieved by initiatives to tackle cataract blindness, much more needs to be done to provide cataract surgery to those in need. Programs for delivering cataract to the vision impaired should not only target the blind, but also those with MSVI who also substantially benefit from treatment and appear to be under-targeted. High quality service provision is essential for inciting demand for cataract surgery, and thus is a key issue along with increasing the number of surgeries. Ophthalmologist training, which takes a long time, needs to be developed urgently in areas of insufficient coverage. Eye care systems in which ophthalmologists can operate successfully and other eye care professionals can work successful also are very important. While all regions with substantial numbers of cataract blind need increased services, females especially need to access cataract surgery more. Culturally appropriate efforts to promote female cataract surgery are an important piece of what needs to be done. Globally,

immense increases in resource mobilization for treating cataract are required. All sources of healthcare financing need to be tapped to develop sustainable eye care systems able to tackle the cataract problem with high quality surgery.

SUMMARY

What was known before

Globally, in 2020, 17.0 million people were blind and nearly 83.5 million were visually impaired by cataract.

What this study adds

The contribution of cataract to blindness and moderate and severe vision impairment (MSVI) by region and the change in this contribution between 2000 and 2020. The change in global age-standardized prevalence of cataract-related blindness and MSVI between 2000 and 2020 and the differences by sex and region.

REFERENCES

- GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. *Lancet Glob Health*. 2021;9:e144–e160. [https://doi.org/10.1016/S2214-109X\(20\)30489-7](https://doi.org/10.1016/S2214-109X(20)30489-7).
- Wang W, Yan W, Fotis K, Prasad NM, Lansingh VC, Taylor HR, et al. Cataract surgical rate and socioeconomics: a global study. *Invest Ophthalmol Vis Sci*. 2016;57:5872–81.
- Lou L, Wang J, Xu P, Ye X, Ye J. Socioeconomic disparity in global burden of cataract: an analysis for 2013 with time trends since 1990. *Am J Ophthalmol*. 2017;180:91–96.
- Wang W, Yan W, Müller A, He M. A global view on output and outcomes of cataract surgery with national indices of socioeconomic development. *Invest Ophthalmol Vis Sci*. 2017;58:3669–76.
- Lim JC, Caballero Arredondo M, Braakhuis AJ, Donaldson PJ. Vitamin C and the lens: new insights into delaying the onset of cataract. *Nutrients*. 2020;12:3142.
- Hodge WG, Whitcher JP, Satariano W. Risk factors for age-related cataracts. *Epidemiol Rev*. 1995;17:336–46.
- Age Related Eye Disease Group. Risk factors associated with age-related nuclear and cortical cataract: a case-control study in the Age-Related Eye Disease Study, AREDS Report No. *Ophthalmology*. 2001;108:1400–8.
- Klein BE, Klein RE, Moss SE. Incidence of cataract surgery in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Am J Ophthalmol*. 1995;119:295–300.
- Caird FI, Garrett CJ. Progression and regression of diabetic retinopathy. *Proc R Soc Med*. 1962;55:477–9.
- Lansingh VC, Carter MJ, Martens M. Global cost-effectiveness of cataract surgery. *Ophthalmology*. 2007;114:1670–8.
- Lansingh VC, Carter MJ. Use of global visual acuity data in a time trade-off approach to calculate the cost utility of cataract surgery. *Arch Ophthalmol*. 2009;127:1183–93.
- Brown GC, Brown MM, Busbee BG. Cost-utility analysis of cataract surgery in the United States for the year 2018. *J Cataract Refract Surg*. 2019;45:927–38.
- Resnikoff S, Lansingh VC, Washburn L, Felch W, Gauthier TM, Taylor HR, et al. Estimated number of ophthalmologists worldwide (International Council of Ophthalmology update): will we meet the needs? *Br J Ophthalmol*. 2020;104:588–92.
- Lou L, Ye X, Xu P, Wang J, Xu Y, Jin K, et al. Association of sex with the global burden of cataract. *JAMA Ophthalmol*. 2018;136:116–21.
- Bourne RRA, Flaxman SR, Braithwaite T. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;5:e888–e897.
- Flaxman SR, Bourne RRA, Resnikoff S. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;5:e1221–e1234.
- Steinmetz JD, Bourne RA, Briant PS, Flaxman SR, Taylor HRB, Jonas JB, et al. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. *Lancet Glob Health*. 2021;9:e144–e160. [https://doi.org/10.1016/S2214-109X\(20\)30489-7](https://doi.org/10.1016/S2214-109X(20)30489-7).
- WHO. Universal eye health: a global action plan 2014–2019. World Health Organization; Geneva: 2013. <https://www.who.int/publications/i/item/universal-eye-health-a-global-action-plan-2014-2019>.
- James SL, Abate D, Hassan Abate K, Abay SM, Abbafati C, Abbasi N, et al. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392:1789–858. [https://doi.org/10.1016/S0140-4906\(18\)32279-7](https://doi.org/10.1016/S0140-4906(18)32279-7)
- RAAB Repository. 2023. <http://raabdata.info>. accessed 1 February 2023.
- Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. GBD 2019 Diseases, Injuries, and Impairments Collaborators. Global burden of 359 diseases, injuries, and impairments, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1204–22. [https://doi.org/10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9).
- Vollset SE, Goren E, Yuan C-W, Cao J, Smith A, Hsiao T, et al. Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. *Lancet*. 2020;396:1285–306. [https://doi.org/10.1016/S0140-4956\(20\)30677-2](https://doi.org/10.1016/S0140-4956(20)30677-2)
- Powe NR, Schein OD, Gieser SC, Tielsch JM, Luthra R, Javitt J, et al. Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team. *Arch Ophthalmol*. 1994;112:239–52. <https://doi.org/10.1001/archophth.1994.01090140115033>.
- Muralikrishnan R, Venkatesh R, Prajna NV, Frick KD. Economic cost of cataract surgery procedures in an established eye care centre in Southern India. *Ophthalmic Epidemiol*. 2004;11:369–80. <https://doi.org/10.1080/09286580490888762>.
- Le HG, Ehrlich JR, Venkatesh R, Srinivasan A, Kolli A, HariPriya A, et al. A Sustainable Model For Delivering High-Quality, Efficient Cataract Surgery In Southern India. *Health Aff*. 2016;35:1783–90. <https://doi.org/10.1377/hlthaff.2016.0562>.
- He M, Chan V, Baruwala E, Gilbert D, Frick KD, Congdon N. Willingness to pay for cataract surgery in rural Southern China. *Ophthalmology*. 2007;114:411–6. <https://doi.org/10.1016/j.ophtha.2006.09.012>.
- Lundstrom M, Behndig A, Kugelberg M, Montan P, Stenevi U, Pesudovs K. The outcome of cataract surgery measured with the Catquest-9SF. *Acta Ophthalmol*. 2011;89:718–23. <https://doi.org/10.1111/j.1755-3768.2009.01801.x>.
- Marques AP, Ramke J, Cairns J, Butt T, Zhang JH, Jones I, et al. The economics of vision impairment and its leading causes: A systematic review. *EclinicalMedicine*. 2022;46:101354. <https://doi.org/10.1016/j.eclinm.2022.101354>.
- Vashist P, Senjam SS, Gupta V, Gupta N, Kumar A. Definition of blindness under National Programme for Control of Blindness: Do we need to revise it? *Indian J Ophthalmol*. 2017;65:92–96. https://doi.org/10.4103/ijoo.IJO_869_16.
- Shekhawat NS, Stock MV, Baze EF, Daly MK, Vollman DE, Lawrence MG, et al. Impact of First Eye versus Second Eye Cataract Surgery on Visual Function and Quality of Life. *Ophthalmology*. 2017;124:1496–503. <https://doi.org/10.1016/j.ophtha.2017.04.014>.
- Gothwal VK, Wright TA, Lamoureux EL, Khadka J, McAlinden C, Pesudovs K. Improvements in visual ability with first-eye, second-eye, and bilateral cataract surgery measured with the visual symptoms and quality of life questionnaire. *J Cataract Refract Surg*. 2011;37:1208–16. <https://doi.org/10.1016/j.jcrs.2011.01.028>.
- Busbee BG, Brown MM, Brown GC, Sharma S. Cost-utility analysis of cataract surgery in the second eye. *Ophthalmology*. 2003;110:2310–7. [https://doi.org/10.1016/S0161-6420\(03\)00796-6](https://doi.org/10.1016/S0161-6420(03)00796-6).
- Frampton G, Harris P, Cooper K, Lotery A, Shepherd J. The clinical effectiveness and cost-effectiveness of second-eye cataract surgery: a systematic review and economic evaluation. *Health Technol Assess*. 2014;18:1–205. <https://doi.org/10.3310/hta18680>.
- Dean WH, Buchan JC, Gichuhi S, Faal H, Mpyet C, Resnikoff S, et al. Ophthalmology training in sub-Saharan Africa: a scoping review. *Eye*. 2021;35:1066–83. <https://doi.org/10.1038/s41433-020-01335-7>.
- Ibrahim N, Ramke J, Pozo-Martin F, Gilbert CE. Willingness to pay for cataract surgery is much lower than actual costs in Zamfara state, northern Nigeria. *Ophthalmic Epidemiol*. 2018;25:227–33. <https://doi.org/10.1080/09286586.2017.1408845>.
- Baruwala E, Tzu J, Congdon N, He M, Frick KD. Reversal in gender valuations of cataract surgery after the implementation of free screening and low-priced high-quality surgery in a rural population of southern China. *Ophthalmic Epidemiol*. 2008;15:99–104. <https://doi.org/10.1080/09286580801999118>.
- Ung L, Jonas JB, Lietman TM, Chodosh J. COVID-19 and the Unfinished Agenda of VISION 2020. *Am J Ophthalmol*. 2021;224:30–35. <https://doi.org/10.1016/j.ajo.2020.11.016>.

FUNDING

Open Access funding enabled and organized by CAUL and its Member Institutions.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Konrad Pesudovs.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

VISION LOSS EXPERT GROUP OF THE GLOBAL BURDEN OF DISEASE STUDY

Konrad Pesudovs¹⁸, Van Charles Lansingh^{19,20,21}, John H. Kempen^{22,23,24,25}, Ian Tapply²⁶, Arthur G. Fernandes^{27,28}, Maria Vittoria Cicinelli^{29,30}, Alessandro Arrigo³¹, Nicolas Leveziel^{32,33}, Serge Resnikoff^{1,4,34}, Hugh R. Taylor³⁵, Tabassom Sedighi³⁶, Seth Flaxman¹⁷, Mukkharrem M. Bikbov³⁷, Tasanee Braithwaite^{38,39}, Alain Bron⁴⁰, Ching-Yu Cheng^{41,42}, Monte A. Del Monte^{43,44}, Joshua R. Ehrlich^{45,46}, Leon B. Ellwein⁴⁷, David Friedman⁴⁸, João M. Furtado⁴⁹, Gus Gazzard⁵⁰, Ronnie George⁵¹, M. Elizabeth Hartnett⁵², Jost B. Jonas⁵³, Rim Kahloun⁵⁴, Moncef Khairallah⁵⁵, Rohit C. Khanna^{56,57,58,59}, Janet Leasher⁶⁰, Julie-Anne Little⁶¹, Vinay Nangia⁶², Michal Nowak⁶³, Tunde Peto⁶⁴, Pradeep Ramulu⁶⁵, Fotis Topouzis⁶⁶, Mitiadis Tsilimbaris⁶⁷, Ya Xing Wang⁶⁸, Ningli Wang⁶⁹ and Rupert Bourne³⁶

¹⁸Medicine & Health, University of New South Wales, Sydney, NSW, Australia. ¹⁹HelpMeSee, Instituto Mexicano de Oftalmologia, Santiago de Querétaro, Mexico. ²⁰University of Miami, Gables, FL, USA. ²¹University of Utah, Salt Lake City, UT, USA. ²²Department of Ophthalmology, Massachusetts Eye and Ear/Shepens Eye Research Institute/Harvard Medical School, Boston, MA, USA. ²³Eye Unit, MyungSung Christian Medical Center (MCM) Comprehensive Specialized Hospital and MyungSun Medical College, Addis Ababa, Ethiopia. ²⁴Department of Ophthalmology, Addis Ababa University, Addis Ababa, Ethiopia. ²⁵Sight for Souls, Bellevue, WA, USA. ²⁶Addenbrooke's Hospital, Cambridge, UK. ²⁷Federal University of Sao Paulo, Sao Paulo/SP, Brazil. ²⁸University of Calgary, Calgary, AB, Canada. ²⁹School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. ³⁰Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy. ³¹IRCCS San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. ³²University of Poitiers, Poitiers, France. ³³CHU de Poitiers, Poitiers, France. ³⁴School of Optometry and Vision Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. ³⁵School of Population and Global Health, University of Melbourne, Carlton, VIC, Australia. ³⁶Vision and Eye Research Institute, Anglia Ruskin University, Cambridge, UK. ³⁷Ufa Eye Research Institute, Ufa, Russia. ³⁸School of Life Course and Population Sciences, King's College London, London, UK. ³⁹The Medical Eye Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK. ⁴⁰University Hospital, Dijon, France. ⁴¹National University of Singapore, Singapore. ⁴²Singapore Eye Research Institute, Singapore. ⁴³University of Michigan, Ann Arbor, MI, USA. ⁴⁴Kellogg Eye Center, Ann Arbor, MI, USA. ⁴⁵Institute for Social Research, University of Michigan, Ann Arbor, MI, USA. ⁴⁶Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA. ⁴⁷National Eye Institute, Bethesda, MD, USA. ⁴⁸Mass Eye and Ear, Harvard Medical School, Boston, MA, USA. ⁴⁹Ribeirão Preto Medical School, University of São Paulo, Sao Paulo, Brazil. ⁵⁰Institute of Ophthalmology UCL & NIHR Biomedical Research Centre, London, UK. ⁵¹Sankara Nethralaya, Medical Research Foundation, 600006 Chennai, India. ⁵²Stanford University, Stanford, CA, USA. ⁵³Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany. ⁵⁴Associated Ophthalmologists of Monastir, Monastir, Tunisia. ⁵⁵Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia. ⁵⁶Allen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye care, L.V. Prasad Eye Institute, Hyderabad, India. ⁵⁷Brien Holden Eye Research Centre, L.V. Prasad Eye Institute, Banjara Hills, Hyderabad, India. ⁵⁸School of Optometry and Vision Science, University of New South Wales, Sydney, NSW, Australia. ⁵⁹University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA. ⁶⁰Nova Southeastern University College for Optometry, Fort Lauderdale, FL, USA. ⁶¹Ulster University, Coleraine, UK. ⁶²Suraj Eye Institute, 559, New colony, Nagpur, India. ⁶³Institute of Optics and Optometry, University of Social Science, 121 Gdanska str., Lodz 90-519, Poland. ⁶⁴Centre for Public Health, Queens University Belfast, Northern Ireland, Belfast, UK. ⁶⁵John Hopkins Wilmer Eye Institute, Baltimore, MD, USA. ⁶⁶1st Department of Ophthalmology, Medical School, Aristotle University of Thessaloniki, Ahepa Hospital, Thessaloniki, Greece. ⁶⁷University of Crete Medical School, Gjoifrakia, Greece. ⁶⁸Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China. ⁶⁹Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

THE GBD 2019 BLINDNESS AND VISION IMPAIRMENT COLLABORATORS

Konrad Pesudovs⁵⁸, Van Charles Lansingh^{70,71}, John H. Kempen^{72,73}, Ian Tapply⁷⁴, Arthur G. Fernandes⁷⁵, Maria Vittoria Cicinelli⁷⁶, Alessandro Arrigo⁷⁷, Nicolas Leveziel^{78,79}, Paul Svitil Briant¹³, Theo Vos^{13,80}, Serge Resnikoff⁵⁸, Hugh R. Taylor³⁵, Tabassom Sedighi⁸¹, Seth Flaxman^{17,82}, Yohannes Habtegiorgis Abate⁸³, Mohammad Abdollahi^{84,85}, Mozhan Abdollahi⁸⁶, Ayele Mamo Abebe⁸⁷, Olumide Abiodun⁸⁸, Richard Gyan Aboagye⁸⁹, Woldu Aberhe Abaha⁹⁰, Hasan Abualruz⁹¹, Hiwa Abubaker Ali⁹², Eman Abu-Gharbieh⁹³, Salahdein Aburuz^{94,95}, Tadele Girum Girum Adal⁹⁶, Mesafint Molla Adane⁹⁷, Isaac Yeboah Addo^{98,99}, Qorinah Estiningtyas Sakilah Adnani¹⁰⁰, Muhammad Sohail Afzal¹⁰¹, Shahin Aghamiri¹⁰², Bright Opoku Ahinkorah¹⁰³, Aqeel Ahmad¹⁰⁴, Sajjad Ahmad^{105,106}, Ali Ahmadi^{107,108}, Ayman Ahmed^{109,110}, Haroon Ahmed¹¹¹, Ahmad Samir Alfaar^{112,113}, Abid Ali¹¹⁴, Syed Shujait Shujait Ali¹¹⁵, Awais Altaf¹¹⁶, Hubert Amu¹¹⁷, Sofia Androudi¹¹⁸, Rodrigo Anguita^{119,120}, Abhishek Anil^{121,122}, Saeid Anvari¹²³, Anayochukwu Edward Anyasodor¹²⁴, Francis Appiah^{125,126}, Jalal Arabloo¹²⁷, Mosab Arafat¹²⁸, Damelash Arede^{129,130}, Reza Arefnezhad¹³¹, Brhane Berhe Aregawi¹³², Akeza Awealom Asgedom¹³³, Tahira Ashraf¹³⁴, Seyyed Shamsadin Athari¹³⁵, Bantalem Tilaye Tilaye Atinafu¹³⁶, Maha Moh'd Wahbi Atout¹³⁷, Alok Atreya¹³⁸, Haleh Ayatollahi^{127,139}, Ahmed Y. Azzam^{140,141}, Hassan Babamohamadi¹⁴², Sara Bagherieh¹⁴³, Yogesh Bahurupi¹⁴⁴, Atif Amin Baig¹⁴⁵, Biswajit Banik^{146,147}, Mainak Bardhan¹⁴⁸, Saurav Basu¹⁴⁹, Kavita Batra¹⁵⁰, Nebiyu Simegnew Bayileyeegn¹⁵¹, Fatemeh Bazvand¹⁵², Addisu Shunu Beyene^{153,154}, Devidas S. Bhagat¹⁵⁵, Akshaya Srikanth Bhagavathula¹⁵⁶, Pankaj Bhardwaj^{157,158}, Sonu Bhaskar^{159,160}, Jasvinder Singh Bhatti¹⁶¹, Mukharram Bikbov¹⁶², Niloufar Bineshar¹⁶³, Marina G. Birck^{164,165}, Veera R. Bitra¹⁶⁶, Tasanee Braithwaite^{167,168}, Katrin Burkart^{13,80}, Yasser Bustanji^{169,170}

Zahid A. Butt^{171,172}, Florentino Luciano Caetano dos Santos¹⁷³, Luis Alberto Cámara^{174,175}, Vera L. A. Carneiro^{176,177}, Muthia Cenderadewi^{178,179}, Eeshwar K. Chandrasekar¹⁸⁰, Vijay Kumar Chattu^{181,182}, Nitin Chitranshi¹⁸³, Hitesh Chopra¹⁸⁴, Dinh-Toi Chu¹⁸⁵, Kaleb Coberly¹³, João M. Coelho¹⁸⁶, Natália Cruz-Martins^{187,188}, Omid Dadras^{189,190}, Xiaochen Dai^{13,80}, Subasish Das¹⁹¹, Ana Maria Dascalu^{192,193}, Mohsen Dashti¹⁹⁴, Maede Dastmardi^{195,196}, Berecha Hundessa Demessa¹⁹⁷, Biniyam Demisse¹⁹⁸, Diriba Dereje¹⁹⁹, Awoke Masrie Asrat Derese¹⁵⁴, Nikolaos Dervenis^{200,201}, Vinoth Gnana Chellaiyan Devanbu²⁰², Thanh Chi Do²⁰³, Thao Huynh Phung Do²⁰⁴, Francisco Winter dos Santos Figueiredo²⁰⁵, Arkadiusz Marian Ziedzic²⁰⁶, Hisham Atan Edinur²⁰⁷, Ferry Efendi²⁰⁸, Joshua R. Ehrlich^{209,210}, Michael Ekholuenetale^{211,212}, Temitope Cyrus Ekundayo²¹³, Iman El Sayed²¹⁴, Muhammed Elhadi²¹⁵, Mohammad Hassan Emamian²¹⁶, Mehdi Emamverdi²¹⁷, Azin Etemadimanesh²¹⁸, Adeniyi Francis Fagbamigbe^{211,219}, Ayesha Fahim²²⁰, Hossein Farrokhpour^{221,222}, Ali Fatehizadeh²²³, Alireza Feizkhah²²⁴, Lorenzo Ferro Desideri²²⁵, Getahun Fetensa²²⁶, Florian Fischer²²⁷, Ali Forouhari^{228,229}, Matteo Foschi^{230,231}, Kayode Raphael Fowobaje^{211,232}, Abhay Motiramji Gaidhane²³³, Aravind P. Gandhi²³⁴, Miglas W. W. Gebregergis²³⁵, Mesfin Gebrehiwot²³⁶, Brhane Gebremariam^{237,238}, Urge Gerema²³⁹, Fariba Ghassemi²⁴⁰, Sherief Ghozy²⁴¹, Mahaveer Golechha²⁴², Pouya Goleji^{243,244}, Bárbara Niegia Garcia Goulart²⁴⁵, Shi-Yang Guan²⁴⁶, Zewdie Gudisa²⁴⁷, Sapna Gupta²⁴⁸, Veer Bala Gupta²⁴⁹, Vivek Kumar Gupta²⁵⁰, Arvin Haj-Mirzaian^{251,252}, Aram Halimi²⁵³, Shahin Hallaj^{254,255}, Samer Hamidi²⁵⁶, Mehdi Harorani²⁵⁷, Hamidreza Hasani²⁵⁸, Demisu Zenbaba Heyi²⁵⁹, Nguyen Quoc Hoan²⁶⁰, Ramesh Holla²⁶¹, Sung Hwi Hong^{262,263}, Mehdi Hosseinzadeh^{264,265}, Chengxi Hu²⁶⁶, John J. Huang²⁶⁷, Hong-Han Huynh²⁶⁸, Segun Emmanuel Ibitoye²⁶⁹, Irena M. Ilic²⁷⁰, Mustapha Immurana²⁷¹, Md. Rabiul Islam²⁷², Sheikh Mohammed Shariful Islam^{273,274}, Chidozie C. D. Iwu²⁷⁵, Louis Jacob^{276,277}, Ammar Abdulrahman Jairoun^{278,279}, Manthan Dilipkumar Janodia²⁸⁰, Shubha Jayaram²⁸¹, Har Ashish Jindal²⁸², Mohammad Jokar^{283,284}, Nitin Joseph²⁸⁵, Charity Ehimwenma Joshua²⁸⁶, Vidya Kadashetti²⁸⁷, Laleh R. Kalankesh²⁸⁸, Rohollah Kalhor^{289,290}, Sagarika Kamath²⁹¹, Himal Kandel^{292,293}, Rami S. Kantar^{294,295}, Ibraheem M. Karaye^{296,297}, Hengameh Kasraei^{298,299}, Soujanya Kaup³⁰⁰, Navjot Kaur³⁰¹, Rimple Jeet Kaur¹²¹, Gbenga A. Kayode^{302,303}, Yousef Saleh Khader³⁰⁴, Himanshu Khajuria³⁰⁵, Rovshan Khalilov^{306,307}, Mahalaqua Nazli Khatib³⁰⁸, Adnan Kisa^{309,310}, Soewarta Kosen³¹¹, Ai Koyanagi³¹², Kewal Krishan³¹³, Mukhtar Kulimbet^{314,315}, Nithin Kumar²⁸⁵, Om P. Kurmi^{316,317}, Chandrakant Lahariya^{318,319}, Tuo Lan³²⁰, Iván Landires^{321,322}, Janet L. Leasher³²³, Munjae Lee^{324,325}, Seung Won Lee³²⁶, Wei-Chen Lee³²⁷, Stephen S. Lim^{13,80}, Julie-Anne Little³²⁸, Preetam Bhalchandra Mahajan³²⁹, Sandeep B. Maharaj^{330,331}, Alireza Mahmoudi²⁴⁰, Razzagh Mahmoudi³³², Kashish Malhotra³³³, Tauqeer Hussain Mallhi³³⁴, Vahid Mansouri³³⁵, Emmanuel Manu¹¹⁷, Roy Rillera Marzo^{336,337}, Andrea Maugeri³³⁸, Colm McAlinden^{339,340}, Wondwosen Mebratu^{341,342}, Tesfahun Mekene Meto³⁴³, Yang Meng³⁴⁴, Abera M. Mersha¹⁹⁸, Tomislav Mestrovic^{13,345}, Le Huu Nhat Minh^{346,347}, Awoke Misganaw^{80,348}, Manish Mishra³⁴⁹, Sanjeev Misra³⁵⁰, Nouh Saad Mohamed^{351,352}, Soheil Mohammadi²²¹, Mustapha Mohammed^{353,354}, Hoda Mojiri-forushani³⁵⁵, Ali H. Mokdad^{13,80}, Hossein Molavi Vardanjani³⁵⁶, Mohammad Ali Moni³⁵⁷, Fateme Montazeri^{358,359}, Maryam Moradi¹⁹⁵, Rohith Motappa²⁸⁵, Parsa Mousavi³⁵⁸, Admir Mulita³⁶⁰, Christopher J. L. Murray^{13,80}, Ganesh R. Naik^{361,362}, Gurudatta Naik³⁶³, Shumaila Nargus¹⁴⁵, Zuhair S. Natto^{364,365}, Biswa Prakash Nayak³⁰⁵, Mohammad Negaresh^{366,367}, Hadush Negash³⁶⁸, Dang H. Nguyen^{369,370}, Phat Tuan Nguyen³⁷¹, Van Thanh Nguyen³⁷², Robina Khan Niazi³⁷³, Osaretin Christabel Okonji³⁷⁴, Andrew T. Olagunju^{375,376}, Matthew Idowu Olatubi³⁷⁷, Michal Ordak³⁷⁸, Uchechukwu Levi Osuagwu^{379,380}, Nikita Ostavnov³⁸¹, Mayowa O. Owolabi^{382,383}, Jagadish Rao Padubidri³⁸⁴, Ashok Pandey^{385,386}, Georgios D. Panos^{387,388}, Shahina Pardhan⁸¹, Seoyeon Park³⁸⁹, Jay Patel^{390,391}, Shrikant Pawar³⁹², Prince Peprah³⁹³, Ionela-Roxana Petcu³⁹⁴, Alireza Peyman²²⁸, Hoang Tran Pham³⁹⁵, Mohsen Pourazizi²²⁸, Nguyen Khoi Quan³⁹⁶, Fakher Rahim^{397,398}, Vafa Rahimi-Movaghar³⁹⁹, Mohammad Hifz Ur Rahman⁴⁰⁰, Sathish Rajaa⁴⁰¹, Shakthi Kumaran Ramasamy⁴⁰², Premkumar Ramasubramani⁴⁰³, Shubham Ranjan⁴⁰⁴, Mohammad-Mahdi Rashidi^{358,405}, Rama Shankar Rath⁴⁰⁶, Annisa Utami Rauf⁴⁰⁷, Salman Rawaf^{408,409}, Amirmasoud Rayati Damavandi⁴¹⁰, Elrashdy Moustafa Mohamed Redwan^{411,412}, Priyanka Roy⁴¹³, Koushik Roy Pramanik⁴¹⁴, Zahra Saadatian^{415,416}, Siamak Sabour¹⁰⁸, Basema Saddik⁴¹⁷, Umar Saeed^{418,419}, Sare Safi^{420,421}, Sher Zaman Safi^{422,423}, Amene Saghazadeh⁴²⁴, Fatemeh Saheb Sharif-Askari⁴²⁵, Amirhossein Sahebkar^{426,427}, Mohammad Ali Sahraian⁴²⁸, Joseph W. Sakshaug^{429,430}, Mohamed A. Saleh^{431,432}, Sara Samadzadeh^{433,434}, Yoseph Leonardo Samodra⁴³⁵, Vijaya Paul Samuel⁴³⁶, Abdallah M. Samy^{437,438}, Aswini Saravanan^{439,440}, Siddharthan Selvaraj⁴⁴¹, Farbod Semnani⁴⁴², Sabyasachi Senapati⁴⁴³, Yashendra Sethi⁴⁴⁴, Seyed Arsalan Seyedi⁴⁴⁵, Allen Seylani⁴⁴⁶, Amira A. Shaheen⁴⁴⁷, Samiah Shahid^{448,449}, Moyad Jamal Shahwan⁴⁵⁰, Masood Ali Shaikh⁴⁵¹, Sunder Sham⁴⁵², Muhammad Aaqib Shamim¹²¹, Mohammed Shannawaz⁴⁵³, Bereket Beyene Shashamo¹⁹⁸, Maryam Shayan^{454,455}, Aminu Shittu⁴⁵⁶, Ivy Shiue^{457,458}, K. M. Shivakumar⁴⁵⁹, Seyed Afshin Shorofi^{460,461}, Migbar Mekonnen Sibhat⁴⁶², Emmanuel Edwar Siddig^{463,464}, Juan Carlos Silva⁴⁶⁵, Jasvinder A. Singh^{466,467}, Paramdeep Singh⁴⁶⁸, Eirini Skiadaresi⁴⁶⁹, Yonatan Solomon⁴⁷⁰, Raúl A. R. C. Sousa⁴⁷¹, Chandrashekhar T. Sreeramareddy⁴⁷², Vladimir I. Starodubov⁴⁷³, Mohana Devi Subramaniam⁴⁷⁴, Sri Susanty⁴⁷⁵, Seyyed Mohammad Tabatabaei^{476,477}, Birhan Tsegaw Taye¹³⁶, Gebrehiwot Teklay⁴⁷⁸, Mohamad-Hani Temsah⁴⁷⁹, Dufera Rikitu Terefa^{480,481}, Jansje Henny Vera Ticoalu⁴⁸², Temesgen Mohammed Toma⁴⁸³, Aristidis Tsatsakis⁴⁸⁴, Guesh Mebrahtom Tsegay⁴⁸⁵, Munkhtuya Tumurkhuu⁴⁸⁶, Biruk Shalmeno Tusa⁴⁸⁷, Sree Sudha Ty⁴⁸⁸, Chukwudi S. Ubah^{489,490}, Muhammad Umair^{101,491}, Tungki Pratama Umar⁴⁹², Rohollah Valizadeh⁴⁹³, Jef Van den Eynde⁴⁹⁴, Stephanie Louise Watson²⁹², Tewodros Eshete Wonde⁴⁹⁵, Guadie Sharew Wondimagegn^{496,497}, Hong Xiao^{498,499}, Yao Yao^{500,501}, Iman Yazdani Nia⁵⁰², Arzu Yiğit⁵⁰³, Yazachew Yismaw^{504,505}, Dong Keon Yon⁵⁰⁶, Naohiro Yonemoto^{507,508}, Yuyi You^{183,292}, Chuanhua Yu⁵⁰⁹, Mikhail Sergeevich Zastrozhin^{510,511}, Hanqing Zhao⁵¹², Makan Ziafati⁵¹³, Magdalena Zielińska⁵¹⁴, Yossef Teshome Zikarg⁵¹⁵, Mohammad Zoladl⁵¹⁶, Jaimie D. Steinmetz¹³ and Rupert Bourne⁸¹

⁷⁰Chief Medical Office, HelpMeSee, New York, NY, USA. ⁷¹Mexican Institute of Ophthalmology, Queretaro, Mexico. ⁷²Department of Ophthalmology, Harvard University, Boston, MA, USA. ⁷³Eye Unit, MyungSung Medical College, Addis Ababa, Ethiopia. ⁷⁴Department of Ophthalmology, Cambridge University Hospitals, Cambridge, UK. ⁷⁵Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, Sao Paulo, Brazil. ⁷⁶Department of Ophthalmology, San Raffaele Scientific Institute, Milano, Italy. ⁷⁷Scientific Institute San Raffaele Hospital, Vita-Salute University, Milan, Italy. ⁷⁸Ophthalmology Department, CHU de Poitiers (Poitiers University Hospital), Poitiers, France. ⁷⁹Unité 1084, National Institute of Health and Medical Research (INSERM), Poitiers, France. ⁸⁰Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA. ⁸¹Vision and Eye Research Institute, Anglia Ruskin University, Cambridge, UK. ⁸²Department of Mathematics, Imperial College London, London, UK. ⁸³Department of Clinical Governance and Quality Improvement, Aleta Wondo Hospital, Aleta Wondo, Ethiopia. ⁸⁴The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran. ⁸⁵School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. ⁸⁶School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. ⁸⁷Pediatrics

Nursing Department, Debre Berhan University, Debre Berhan, Ethiopia. ⁸⁸Department of Community Medicine, Babcock University, Ilishan-Remo, Nigeria. ⁸⁹Department of Family and Community Health, University of Health and Allied Sciences, Ho, Ghana. ⁹⁰Department of Adult Health Nursing, Aksum University, Aksum, Ethiopia. ⁹¹Department of Nursing, Al Zaytoonah University of Jordan, Amman, Jordan. ⁹²Department of Banking and Finance, University of Human Development, Sulaymaniyah, Iraq. ⁹³Clinical Sciences Department, University of Sharjah, Sharjah, United Arab Emirates. ⁹⁴Department of Therapeutics, United Arab Emirates University, Al Ain, United Arab Emirates. ⁹⁵College of Pharmacy, University of Jordan, Amman, Jordan. ⁹⁶Department of Public Health, Wolkite University, Wolkite, Ethiopia. ⁹⁷College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia. ⁹⁸Centre for Social Research in Health, University of New South Wales, Sydney, NSW, Australia. ⁹⁹Quality and Systems Performance Unit, Cancer Institute NSW, Sydney, NSW, Australia. ¹⁰⁰Faculty of Medicine, Universitas Padjadjaran (Padjadjaran University), Bandung, Indonesia. ¹⁰¹Department of Life Sciences, University of Management and Technology, Lahore, Pakistan. ¹⁰²Department of Biotechnology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹⁰³School of Public Health, University of Technology Sydney, Sydney, NSW, Australia. ¹⁰⁴Department of Medical Biochemistry, Shaqra University, Shaqra, Saudi Arabia. ¹⁰⁵Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan. ¹⁰⁶Department of Natural Sciences, Lebanese American University, Beirut, Lebanon. ¹⁰⁷Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran. ¹⁰⁸Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹⁰⁹Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan. ¹¹⁰Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland. ¹¹¹Department of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan. ¹¹²Department of Ophthalmology, University of Leipzig Medical Center, Leipzig, Germany. ¹¹³Department of Ophthalmology, Charité Universitätsmedizin Berlin (Charité Medical University Berlin), Berlin, Germany. ¹¹⁴Department of Zoology, Abdul Wali Khan University Mardan, Mardan, Pakistan. ¹¹⁵Center for Biotechnology and Microbiology, University of SWAT, Swat, Pakistan. ¹¹⁶Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, Lahore, Pakistan. ¹¹⁷Department of Population and Behavioural Sciences, University of Health and Allied Sciences, Ho, Ghana. ¹¹⁸Department of Medicine, University of Thessaly, Volos, Greece. ¹¹⁹Department of Ophthalmology, Inselspital, Bern, Switzerland. ¹²⁰Department of Vitreoretinal, Moorfields Eye Hospital, London, UK. ¹²¹Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India. ¹²²All India Institute of Medical Sciences, Bhubaneswar, India. ¹²³Regenerative Medicine, Organ Procurement and Transplantation Multi-disciplinary Center, Guilin University of Medical Sciences, Rasht, Iran. ¹²⁴School of Dentistry and Medical Sciences, Charles Sturt University, Orange, NSW, Australia. ¹²⁵Department of Social Sciences, Berekum College of Education, Berekum, Ghana. ¹²⁶School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. ¹²⁷Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. ¹²⁸College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates. ¹²⁹College of Art and Science, Ottawa University, Surprise, AZ, USA. ¹³⁰School of Life Sciences, Arizona State University, Tempe, AZ, USA. ¹³¹Department of Anatomy, Shiraz University of Medical Sciences, Shiraz, Iran. ¹³²College of Medicine and Health Sciences, Adigrat University, Adigrat, Ethiopia. ¹³³Department of Environmental Health, Mekelle University, Mekelle, Ethiopia. ¹³⁴University Institute of Radiological Sciences and Medical Imaging Technology, The University of Lahore, Lahore, Pakistan. ¹³⁵Department of Immunology, Zanjan University of Medical Sciences, Zanjan, Iran. ¹³⁶School of Nursing and Midwifery, Debre Berhan University, Debre Berhan, Ethiopia. ¹³⁷Faculty of Nursing, Philadelphia University, Amman, Jordan. ¹³⁸Department of Forensic Medicine, Lumbini Medical College, Palpa, Nepal. ¹³⁹Department of Health Information Management, Iran University of Medical Sciences, Tehran, Iran. ¹⁴⁰Department of Neurovascular Research, Nested Knowledge, Inc., Saint Paul, MN, USA. ¹⁴¹Faculty of Medicine, October 6 University, 6th of October City, Egypt. ¹⁴²Department of Nursing, Semnan University of Medical Sciences and Health Services, Semnan, Iran. ¹⁴³School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. ¹⁴⁴Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Rishikesh, India. ¹⁴⁵University Institute of Public Health, The University of Lahore, Lahore, Pakistan. ¹⁴⁶Institute of Health and Wellbeing (IHW), Federation University Australia, Melbourne, VIC, Australia. ¹⁴⁷Manna Institute, University of New England, Armidale, NSW, Australia. ¹⁴⁸Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA. ¹⁴⁹Department of Academics, Indian Institute of Public Health, Gurgaon, India. ¹⁵⁰Department of Medical Education, University of Nevada, Las Vegas, Las Vegas, NV, USA. ¹⁵¹Department of Surgery, Jimma University, jimma, Ethiopia. ¹⁵²Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. ¹⁵³School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia. ¹⁵⁴School of Public Health, Haramaya University, Harar, Ethiopia. ¹⁵⁵Department of Forensic Chemistry, Government Institute of Forensic Science, Aurangabad, Aurangabad, India. ¹⁵⁶Department of Public Health, North Dakota State University, Fargo, ND, USA. ¹⁵⁷Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India. ¹⁵⁸School of Public Health, All India Institute of Medical Sciences, Jodhpur, India. ¹⁵⁹Global Health Neurology Lab, NSW Brain Clot Bank, Sydney, NSW, Australia. ¹⁶⁰Department of Neurology and Neurophysiology, South West Sydney Local Health District and Liverpool Hospital, Sydney, NSW, Australia. ¹⁶¹Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India. ¹⁶²Epidemiology Department, Ufa Eye Research Institute, Ufa, Russia. ¹⁶³Department of Ophthalmology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹⁶⁴Department of Medicine, Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada. ¹⁶⁵Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada. ¹⁶⁶Faculty of Health Sciences, University of Botswana, Gaborone, Botswana. ¹⁶⁷Ophthalmology Department, Moorfields Eye Hospital NHS Foundation Trust, London, UK. ¹⁶⁸International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. ¹⁶⁹Department of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, Amman, Jordan. ¹⁷⁰Department of Basic Biomedical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ¹⁷¹School of Public Health and Health Systems, University of Waterloo, Waterloo, ON, Canada. ¹⁷²Al Shifa School of Public Health, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan. ¹⁷³Harvard Business School, Harvard University, Boston, MA, USA. ¹⁷⁴Internal Medicine Department, Hospital Italiano de Buenos Aires (Italian Hospital of Buenos Aires), Buenos Aires, Argentina. ¹⁷⁵Board of Directors, Argentine Society of Medicine, Buenos Aires, Argentina. ¹⁷⁶School of Sciences, University of Minho, Braga, Portugal. ¹⁷⁷Association of Licensed Optometry Professionals, Linda-a-Velha, Portugal. ¹⁷⁸College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, QLD, Australia. ¹⁷⁹Public Health Department, University of Mataram, Mataram, Indonesia. ¹⁸⁰Department of Anesthesiology and Perioperative Medicine, University of Rochester, Rochester, NY, USA. ¹⁸¹Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. ¹⁸²Saveetha Dental College, Saveetha University, Chennai, India. ¹⁸³Macquarie Medical School, Macquarie University, Sydney, NSW, Australia. ¹⁸⁴Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India. ¹⁸⁵Center for Biomedicine and Community Health, VNU-International School, Hanoi, Viet Nam. ¹⁸⁶University Hospital Center of Porto, University of Porto, Porto, Portugal. ¹⁸⁷Therapeutic and Diagnostic Technologies, Cooperativa de Ensino Superior Politécnico e Universitário (Polytechnic and University Higher Education Cooperative), Gandra, Portugal. ¹⁸⁸Institute for Research and Innovation in Health, University of Porto, Porto, Portugal. ¹⁸⁹Department of Addiction Medicine, Haukland University Hospital, Bergen, Norway. ¹⁹⁰Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. ¹⁹¹Ingram School of Engineering, Texas State University, San Marcos, TX, USA. ¹⁹²Ophthalmology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ¹⁹³Ophthalmology Department, Emergency University Hospital Bucharest, Bucuresti, Romania. ¹⁹⁴Department of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran. ¹⁹⁵Iran University of Medical Sciences, Tehran, Iran. ¹⁹⁶Tehran University of Medical Science, Tehran University of Medical Sciences, Tehran, Iran. ¹⁹⁷USAID-JSI, Jimma University, Addis Ababa, Ethiopia. ¹⁹⁸Department of Nursing, Arba Minch University, Arba Minch, Ethiopia. ¹⁹⁹Department of Biomedical Sciences, Jimma University, Jimma, Ethiopia. ²⁰⁰St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK. ²⁰¹Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece. ²⁰²Department of Community Medicine, Chettinad Hospital and Research Institute, Chennai, India. ²⁰³Department of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam. ²⁰⁴Department of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Viet Nam. ²⁰⁵Epidemiology and Data Analysis Laboratory, University Center FMABC, Santo André, Brazil. ²⁰⁶Department of Conservative Dentistry with Endodontics, Medical University of Silesia, Katowice, Poland. ²⁰⁷School of Health Sciences, Universiti Sains Malaysia (University of Science Malaysia), Kubang Kerian, Malaysia. ²⁰⁸Advanced Nursing Department, Universitas Airlangga, Surabaya, Indonesia. ²⁰⁹Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, GA, USA. ²¹⁰Institute for Health Care Policy and Innovation, University of Michigan, Ann Arbor, MI, USA. ²¹¹Department of Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria. ²¹²Faculty of Public Health, University of Ibadan, Ibadan, Nigeria. ²¹³Department of Biological Sciences, University of Medical Sciences, Ondo, Ondo, Nigeria. ²¹⁴Biomedical Informatics and Medical Statistics Department, Alexandria University, Alexandria, Egypt. ²¹⁵Faculty of Medicine, University of Tripoli, Tripoli, Libya. ²¹⁶Ophthalmic Epidemiology Research Center, Shahrud University of Medical Sciences, Shahrud, Iran. ²¹⁷Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA, USA. ²¹⁸Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, MD, USA. ²¹⁹Research Centre for Healthcare and Community, Coventry University, Coventry, UK. ²²⁰Department of Oral Biology, The University of Lahore, Lahore, Pakistan. ²²¹School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ²²²Endocrinology and Metabolism Research Institute, Non-Communicable Diseases Research Center (NCDRC), Tehran, Iran. ²²³Department of Environmental Health Engineering, Isfahan University of Medical Sciences, Isfahan, Iran. ²²⁴Department of Social Medicine and Epidemiology, Guilin University of Medical Sciences, Rasht, Iran. ²²⁵University Eye Clinic, University of Genoa, Genoa, Italy. ²²⁶Department of Nursing, Wollega University, Nekemte, Ethiopia. ²²⁷Institute of Public Health, Charité Universitätsmedizin Berlin (Charité Medical University Berlin), Berlin, Germany. ²²⁸Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran. ²²⁹Emergency Department, Isfahan University of Medical Sciences, Isfahan, Iran. ²³⁰Department of Biotechnological and Applied Clinical Sciences (DISCAB), Multiple Sclerosis Research Center, L'Aquila, Italy. ²³¹Department of Neuroscience, Multiple Sclerosis Research Center, Ravenna, Italy. ²³²Child Survival Unit, Centre for African Newborn Health and Nutrition, Ibadan, Nigeria. ²³³Department of

Community Medicine, Datta Meghe Institute of Medical Sciences, Wardha, India.²³⁴Department of Community Medicine, ESIC Medical College & Hospital, Hyderabad, India.²³⁵Department of Midwifery, Adigrat University, Adigrat, Ethiopia.²³⁶Department of Environmental Health, Wollo University, Dessie, Ethiopia.²³⁷Department of Health, Policy Research Institute, Mekelle, Ethiopia.²³⁸Simon Fraser University, Mekelle, Ethiopia.²³⁹Department of Public Health, Jimma University, Jimma, Ethiopia.²⁴⁰Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran.²⁴¹Department of Radiology, Mayo Clinic, Rochester, MN, USA.²⁴²Health Systems and Policy Research Department, Indian Institute of Public Health, Gandhinagar, India.²⁴³Department of Genetics, Sana Institute of Higher Education, Sari, Iran.²⁴⁴Universal Scientific Education and Research Network (USERN), Kermanshah University of Medical Sciences, Kermanshah, Iran.²⁴⁵Postgraduate Program in Epidemiology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.²⁴⁶Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China.²⁴⁷Department of Anesthesia, Madda Walabu University, Goba, Ethiopia.²⁴⁸Toxicology Department, Shiram Institute for Industrial Research, Delhi, India.²⁴⁹School of Medicine, Deakin University, Geelong, VIC, Australia.²⁵⁰Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.²⁵¹Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.²⁵²Obesity Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.²⁵³Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.²⁵⁴Department of Ophthalmology, Thomas Jefferson University, Philadelphia, PA, USA.²⁵⁵Department of Ophthalmology, University of California San Diego, La Jolla, CA, USA.²⁵⁶School of Health and Environmental Studies, Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates.²⁵⁷Department of Nursing, Arak University of Medical Sciences, Arak, Iran.²⁵⁸Department of Ophthalmology, Iran University of Medical Sciences, Karaj, Iran.²⁵⁹Department of Public Health, Mada Walabu University, Goba, Ethiopia.²⁶⁰School of Dentistry, Hanoi Medical University, Hanoi, Viet Nam.²⁶¹Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India.²⁶²Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.²⁶³Research Department, Electronic Medical Records for the Developing World, York, UK.²⁶⁴Institute of Research and Development, Duy Tan University, Da Nang, Viet Nam.²⁶⁵Department of Computer Science, University of Human Development, Sulaymaniyah, Iraq.²⁶⁶Department of Psychology, Tsinghua University, Beijing, China.²⁶⁷Department of Ophthalmology and Visual Science, Yale University, New Haven, CT, USA.²⁶⁸School of Biotechnology, Tan Tao University, Long An, Viet Nam.²⁶⁹Department of Health Promotion and Education, University of Ibadan, Ibadan, Nigeria.²⁷⁰Faculty of Medicine, University of Belgrade, Belgrade, Serbia.²⁷¹Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana.²⁷²Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh.²⁷³Institute for Physical Activity and Nutrition, Deakin University, Burwood, VIC, Australia.²⁷⁴Sydney Medical School, University of Sydney, Sydney, NSW, Australia.²⁷⁵School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa.²⁷⁶Research and Development Unit, Biomedical Research Networking Center for Mental Health Network (CiberSAM), Sant Boi de Llobregat, Spain.²⁷⁷Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le Bretonneux, France.²⁷⁸Department of Clinical Pharmacy, University of Science Malaysia, Penang, Malaysia.²⁷⁹Department of Health and Safety, United Arab Emirates University, Dubai, United Arab Emirates.²⁸⁰Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India.²⁸¹Department of Biochemistry, Government Medical College, Mysuru, India.²⁸²National Health System Resource Centre, Ministry of Health & Family Welfare, New Delhi, India.²⁸³Zoonoses Research Center, Islamic Azad University, Karaj, Iran.²⁸⁴Department of Clinical Sciences, Jahrom University of Medical Sciences, Jahrom, Iran.²⁸⁵Department of Community Medicine, Manipal Academy of Higher Education, Mangalore, India.²⁸⁶Department of Economics, National Open University, Benin City, Nigeria.²⁸⁷Department of Oral and Maxillofacial Pathology, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, India.²⁸⁸Social Determinants of Health Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.²⁸⁹Institute for Prevention of Non-communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.²⁹⁰Health Services Management Department, Qazvin University of Medical Sciences, Qazvin, Iran.²⁹¹Manipal Institute of Management, Manipal Academy of Higher Education, Manipal, India.²⁹²Save Sight Institute, University of Sydney, Sydney, NSW, Australia.²⁹³Sydney Eye Hospital, South Eastern Sydney Local Health District, Sydney, NSW, Australia.²⁹⁴The Hansjörg Wyss Department of Plastic and Reconstructive Surgery, Nab'a Al-Hayat Foundation for Medical Sciences and Health Care, New York, NY, USA.²⁹⁵Department of Cleft Lip and Palate Surgery, Global Smile Foundation, Norwood, MA, USA.²⁹⁶School of Health Professions and Human Services, Hofstra University, Hempstead, NY, USA.²⁹⁷Department of Anesthesiology, Montefiore Medical Center, Bronx, NY, USA.²⁹⁸Eye Research Center, Iran University of Medical Sciences, Tehran, Iran.²⁹⁹Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.³⁰⁰Department of Ophthalmology, Yenepoya Medical College, Mangalore, India.³⁰¹Department of ENT, Dr. B. R. Ambedkar State Institute of Medical Sciences (AIMS), Mohali, India.³⁰²International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.³⁰³Julius Centre for Health Sciences and Primary Care, Utrecht University, Utrecht, Netherlands.³⁰⁴Department of Public Health, Jordan University of Science and Technology, Irbid, Jordan.³⁰⁵Amity Institute of Forensic Sciences, Amity University, Noida, India.³⁰⁶Department of Biophysics and Biochemistry, Baku State University, Baku, Azerbaijan.³⁰⁷Azerbaijan State University of Economics (UNEC), Baku, Azerbaijan.³⁰⁸Global Consortium for Public Health Research, Datta Meghe Institute of Higher Education and Research, Wardha, India.³⁰⁹School of Health Sciences, Kristiania University College, Oslo, Norway.³¹⁰Department of International Health and Sustainable Development, Tulane University, New Orleans, LA, USA.³¹¹Independent Consultant, Jakarta, Indonesia.³¹²San Juan de Dios Sanitary Park, Barcelona, Spain.³¹³Department of Anthropology, Panjab University, Chandigarh, India.³¹⁴Department of Health Research, Almaty, Kazakhstan.³¹⁵Atchabarov Scientific Research Institute of Fundamental and Applied Medicine, Kazakh National Medical University, Almaty, Kazakhstan.³¹⁶Faculty of Health and Life Sciences, Coventry University, Coventry, UK.³¹⁷Department of Medicine, McMaster University, Hamilton, ON, Canada.³¹⁸Department of Health Policy and Strategy, Foundation for People-centric Health Systems, New Delhi, India.³¹⁹SD Gupta School of Public Health, Indian Institute of Health Management Research University, Jaipur, India.³²⁰Department of Surgery, Washington University in St. Louis, Saint Louis, MO, USA.³²¹Unit of Genetics and Public Health, Institute of Medical Sciences, Las Tablas, Panama.³²²Ministry of Health, Herrera, Panama.³²³College of Optometry, Nova Southeastern University, Fort Lauderdale, FL, USA.³²⁴Department of Medical Humanities and Social Medicine, Aju University School of Medicine, Suwon, South Korea.³²⁵Medial Research Collaborating Center, Aju University Medical Center, Suwon, South Korea.³²⁶Department of Precision Medicine, Sungkyunkwan University, Suwon-si, South Korea.³²⁷Department of Internal Medicine, University of Texas, Galveston, TX, USA.³²⁸School of Biomedical Sciences, Coleraine, UK.³²⁹Department of Community Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Karaikal, India.³³⁰School of Pharmacy, University of the West Indies, St. Augustine, Trinidad and Tobago.³³¹Fellow, Planetary Health Alliance, Boston, MA, USA.³³²Department of Food Hygiene and Safety, Qazvin University of Medical Sciences, Qazvin, Iran.³³³Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India.³³⁴Department of Clinical Pharmacy, Jouf University, Sakaka, Saudi Arabia.³³⁵Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.³³⁶Department of Public Health, Management and Science University, Shah Alam, Malaysia.³³⁷Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Subang Jaya, Malaysia.³³⁸Department GF Ingrassia, University of Catania, Catania, Italy.³³⁹Department of Ophthalmology, Princess of Wales Hospital, Wales, UK.³⁴⁰School of Optometry and Vision Sciences, Cardiff University, Cardiff, UK.³⁴¹Department of Epidemiology and Biostatistics, Wollo University, Dessie, Ethiopia.³⁴²Department of Research, Performance Monitoring and Accountability 2020-Ethiopia, Addis Ababa, Ethiopia.³⁴³Department of Public Health, Arba Minch University, Arba Minch, Ethiopia.³⁴⁴Eye Center, Wuhan University, Wuhan, China.³⁴⁵University Centre Varazdin, University North, Varazdin, Croatia.³⁴⁶International Ph.D. Program in Medicine, Taipei Medical University, Taipei, Taiwan.³⁴⁷Research Center for Artificial Intelligence in Medicine, Taipei Medical University, Taipei, Taiwan.³⁴⁸National Data Management Center for Health, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.³⁴⁹Department of Biomedical Sciences, Mercer University School of Medicine, Macon, GA, USA.³⁵⁰Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India.³⁵¹Molecular Biology Unit, Sirius Training and Research Centre, Khartoum, Sudan.³⁵²Bio-Statistical and Molecular Biology Department, Sirius Training and Research Centre, Khartoum, Sudan.³⁵³Department of Clinical Pharmacy and Pharmacy Practice, Ahmadu Bello University, Zaria, Nigeria.³⁵⁴School of Pharmaceutical Sciences, Universiti Sains Malaysia (University of Science Malaysia), Penang, Malaysia.³⁵⁵Department of Pharmacology, Abadan School of Medical Sciences, Abadan, Iran.³⁵⁶Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran.³⁵⁷School of Health & Rehabilitation Sciences, The University of Queensland, Brisbane, QLD, Australia.³⁵⁸Non-communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.³⁵⁹School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.³⁶⁰Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.³⁶¹College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.³⁶²Department of Engineering, Western Sydney University, Sydney, NSW, Australia.³⁶³Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.³⁶⁴Department of Dental Public Health, King Abdulaziz University, Jeddah, Saudi Arabia.³⁶⁵Department of Health Policy and Oral Epidemiology, Harvard University, Boston, MA, USA.³⁶⁶Independent Consultant, Tehran, Iran.³⁶⁷Department of Internal Medicine, Ardabil University of Medical Science, Ardabil, Iran.³⁶⁸Department of Medical Laboratory Sciences, Adigrat University, Adigrat, Ethiopia.³⁶⁹Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA.³⁷⁰Department of Medical Engineering, University of South Florida, Tampa, FL, USA.³⁷¹Department of Surgery, Danang Family Hospital, Danang, Viet Nam.³⁷²Department of General Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam.³⁷³International Islamic University Islamabad, Islamabad, Pakistan.³⁷⁴School of Pharmacy, University of the Western Cape, Cape Town, South Africa.³⁷⁵Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.³⁷⁶Department of Psychiatry, University of Lagos, Lagos, Nigeria.³⁷⁷Department of Nursing Science, Bowen University, Iwo, Nigeria.³⁷⁸Department of Pharmacotherapy and Pharmaceutical Care, Medical University of Warsaw, Warsaw, Poland.³⁷⁹School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.³⁸⁰Department of Optometry and Vision Science, University of KwaZulu-Natal, KwaZulu-Natal, South Africa.³⁸¹Laboratory of Public Health Indicators Analysis and Health

Digitalization, Moscow Institute of Physics and Technology, Dolgoprudny, Russia.³⁸²Department of Medicine, University of Ibadan, Ibadan, Nigeria.³⁸³Department of Medicine, University College Hospital, Ibadan, Ibadan, Nigeria.³⁸⁴Department of Forensic Medicine and Toxicology, Kasturba Medical College, Mangalore, Mangalore, India.³⁸⁵Research Department, Nepal Health Research Council, Kathmandu, Nepal.³⁸⁶Research Department, Public Health Research Society Nepal, Kathmandu, Nepal.³⁸⁷Department of Ophthalmology, Nottingham University Hospitals, QMC Campus, Nottingham, UK.³⁸⁸Division of Ophthalmology & Visual Sciences, University of Nottingham, Nottingham, UK.³⁸⁹Yonsei University College of Medicine, Seodaemun-gu, South Korea.³⁹⁰Global Health Governance Programme, University of Edinburgh, Edinburgh, UK.³⁹¹School of Dentistry, University of Leeds, Leeds, UK.³⁹²Department of Genetics, Yale University, New Haven, CT, USA.³⁹³Centre for Primary Health Care and Equity, University of New South Wales, Kensington, NSW, Australia.³⁹⁴Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania.³⁹⁵School of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam.³⁹⁶College of Health Sciences, VinUniversity, Hanoi, Viet Nam.³⁹⁷Department of Health Sciences, Cihan University Sulaimaniya, Sulaymaniyah, Iraq.³⁹⁸Cihan University Sulaimaniya Research Center (CUSRC), Sulaymaniyah, Iraq.³⁹⁹Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.⁴⁰⁰Manipal TATA Medical College, Manipal Academy of Higher Education, Manipal, India.⁴⁰¹Department of Community Medicine, Employees' State Insurance Model Hospital, Chennai, India.⁴⁰²Department of Radiology, Stanford University, Stanford, CA, USA.⁴⁰³Department of Community Medicine, Mahatma Gandhi Medical College and Research Institute, Puducherry, India.⁴⁰⁴School of Humanities and Social Sciences, Indian Institute of Technology Mandi, Mandi, India.⁴⁰⁵Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.⁴⁰⁶Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Gorakhpur, Gorakhpur, India.⁴⁰⁷Department of Health Behaviour, Environment, and Social Medicine, Gadjah Mada University, Yogyakarta, Indonesia.⁴⁰⁸Department of Primary Care and Public Health, Imperial College London, London, UK.⁴⁰⁹Academic Public Health England, Public Health England, London, UK.⁴¹⁰Department of Medicine, Tehran University of Medical Sciences, Tehran, Iran.⁴¹¹Department Biological Sciences, King Abdulaziz University, Jeddah, Egypt.⁴¹²Department of Protein Research, Research and Academic Institution, Alexandria, Egypt.⁴¹³Department of Labour, Directorate of Factories, Government of West Bengal, Kolkata, India.⁴¹⁴Department of Biostatistics and Epidemiology, International Institute for Population Sciences, Mumbai, India.⁴¹⁵Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran.⁴¹⁶Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.⁴¹⁷Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.⁴¹⁸Multidisciplinary Laboratory Foundation University School of Health Sciences (FUSH), Foundation University, Islamabad, Pakistan.⁴¹⁹International Center of Medical Sciences Research (ICMSR), Islamabad, Pakistan.⁴²⁰Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.⁴²¹Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.⁴²²Faculty of Medicine, Bioscience and Nursing, MAHSA University, Selangor, Malaysia.⁴²³Interdisciplinary Research Centre in Biomedical Materials (IRCBM), COMSATS Institute of Information Technology, Lahore, Pakistan.⁴²⁴Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran.⁴²⁵Sharjah Institute of Medical Sciences, University of Sharjah, Sharjah, United Arab Emirates.⁴²⁶Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.⁴²⁷Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.⁴²⁸Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, Iran.⁴²⁹Ludwig Maximilian University of Munich, Munich, Germany.⁴³⁰Institute for Employment Research, Nuremberg, Germany.⁴³¹College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.⁴³²Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.⁴³³Department of Neurology, Charité Universitätsmedizin Berlin (Charité Medical University Berlin), Berlin, Germany.⁴³⁴Department of Neurology, University of Southern Denmark, Odense, Denmark.⁴³⁵School of Public Health, Taipei Medical University, Taipei, Taiwan.⁴³⁶Department of Anatomy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.⁴³⁷Department of Entomology, Ain Shams University, Cairo, Egypt.⁴³⁸Medical Ain Shams Research Institute (MASRI), Ain Shams University, Cairo, Egypt.⁴³⁹Department of Pharmacology and Research, All India Institute of Medical Sciences, Jodhpur, India.⁴⁴⁰Indira Gandhi Medical College and Research Institute, Puducherry, India.⁴⁴¹Faculty of Dentistry, AIMST University, Bedong, Malaysia.⁴⁴²Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.⁴⁴³Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India.⁴⁴⁴Department of Medicine and Surgery, Government Doon Medical College, Dehradun, India.⁴⁴⁵Endocrinology and Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran.⁴⁴⁶National Heart, Lung, and Blood Institute, National Institute of Health, Rockville, MD, USA.⁴⁴⁷Public Health Division, An-Najah National University, Nablus, Palestine.⁴⁴⁸Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, Pakistan.⁴⁴⁹Research Centre for Health Sciences (RCHS), The University of Lahore, Lahore, Pakistan.⁴⁵⁰Department of Clinical Sciences, Al-Quds University, Ajman, United Arab Emirates.⁴⁵¹Independent Consultant, Karachi, Pakistan.⁴⁵²Department of Pathology and Laboratory Medicine, Northwell Health, New York City, NY, USA.⁴⁵³Amity Institute of Public Health, Amity University, Noida, India.⁴⁵⁴Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.⁴⁵⁵Ophthalmic Research Center (ORC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.⁴⁵⁶Department of Veterinary Public Health and Preventive Medicine, Usmanu Danfodiyo University, Sokoto, Sokoto, Nigeria.⁴⁵⁷Center for Environmental and Respiratory Health Research, University of Oulu, Oulu, Finland.⁴⁵⁸National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli, Taiwan.⁴⁵⁹Department of Public Health Dentistry, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, India.⁴⁶⁰Department of Medical-Surgical Nursing, Mazandaran University of Medical Sciences, Sari, Iran.⁴⁶¹Department of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.⁴⁶²Department of Pediatrics and Child Health Nursing, Dilla University, Dilla, Ethiopia.⁴⁶³Unit of Basic Medical Sciences, University of Khartoum, Khartoum, Sudan.⁴⁶⁴Department of Medical Microbiology and Infectious Diseases, Erasmus University, Rotterdam, Netherlands.⁴⁶⁵Family, Health Promotion, and Life Course Department, Pan American Health Organization, Bogota, Colombia.⁴⁶⁶School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.⁴⁶⁷Department of Medicine Service, US Department of Veterans Affairs (VA), Birmingham, AL, USA.⁴⁶⁸Department of Radiodiagnosis, All India Institute of Medical Sciences, Bathinda, India.⁴⁶⁹Department of Ophthalmology, Hywel Dda University Health Board, Llanelli, UK.⁴⁷⁰Department of Nursing, Dire Dawa University, Dire Dawa, Ethiopia.⁴⁷¹Directive Board, Associação de Profissionais Licenciados de Optometria (Association of Licensed Optometry Professionals), Linda-a-Velha, Portugal.⁴⁷²Division of Community Medicine, International Medical University, Kuala Lumpur, Malaysia.⁴⁷³Federal Research Institute for Health Organization and Informatics of the Ministry of Health (FRIHO), Moscow, Russia.⁴⁷⁴Soonchunhyang University, Vision Research Foundation, Cheonan-si, South Korea.⁴⁷⁵Nursing Professional Education Study Program, University Halu Oleo, Kendari, Indonesia.⁴⁷⁶Department of Medical Informatics, Mashhad University of Medical Sciences, Mashhad, Iran.⁴⁷⁷Clinical Research Development Unit, Mashhad University of Medical Sciences, Mashhad, Iran.⁴⁷⁸Department of Clinical Pharmacy, Mekelle University, Mekelle, Ethiopia.⁴⁷⁹Pediatric Intensive Care Unit, King Saud University, Riyadh, Saudi Arabia.⁴⁸⁰Outpatient Department, Wollega University, Bedele town, Ethiopia.⁴⁸¹Department of Public Health, Wollega University, Nekemte, Ethiopia.⁴⁸²Faculty of Public Health, Universitas Sam Ratulangi, Manado, Indonesia.⁴⁸³Department of Public Health, Arba Minch College of Health Sciences, Arba Minch, Ethiopia.⁴⁸⁴Department of Medicine, University of Crete, Heraklion, Greece.⁴⁸⁵Department of Nursing, Aksum University, Aksum, Ethiopia.⁴⁸⁶Department of Physiology, East Carolina University, Greenville, NC, USA.⁴⁸⁷Department of Epidemiology and Biostatistics, Haramaya University, Harar, Ethiopia.⁴⁸⁸Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, India.⁴⁸⁹Department of Public Health, East Carolina University, Greenville, NC, USA.⁴⁹⁰College of Public Health, Temple University, Philadelphia, PA, USA.⁴⁹¹Medical Genomics Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.⁴⁹²Division of Surgery and Interventional Science, University College London, London, UK.⁴⁹³Urmia University of Medical Sciences, Urmia, Iran.⁴⁹⁴Department of Cardiovascular Sciences, Katholieke Universiteit Leuven (University of Leuven), Leuven, Belgium.⁴⁹⁵Department of Public Health, Debre Markos University, Debre Markos, Ethiopia.⁴⁹⁶Department of Ophthalmology Research, Queen Mamohato Memorial Hospital, Maseru, Lesotho.⁴⁹⁷Ophthalmology Unit, Bahir Dar University, Bahirdar, Ethiopia.⁴⁹⁸School of Public Health, Zhejiang University, Zhejiang, China.⁴⁹⁹Department of Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.⁵⁰⁰China Center for Health Development Studies, Peking University, Beijing, China.⁵⁰¹Center for the Study of Aging and Human Development, Duke University, Durham, NC, USA.⁵⁰²The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.⁵⁰³Department of Health Management, Süleyman Demirel Üniversitesi (Süleyman Demirel University), Isparta, Türkiye.⁵⁰⁴Department of Pharmacology, Bahir Dar University, Bahir Dar, Ethiopia.⁵⁰⁵Pharmacy Department, Alkan Health Science, Business and Technology College, Bahir Dar, Ethiopia.⁵⁰⁶Department of Pediatrics, Kyung Hee University, Seoul, South Korea.⁵⁰⁷Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Kodaira, Japan.⁵⁰⁸Department of Public Health, Juntendo University, Tokyo, Japan.⁵⁰⁹Department of Epidemiology and Biostatistics, Wuhan University, Wuhan, China.⁵¹⁰Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.⁵¹¹Addictology Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia.⁵¹²College of Traditional Chinese Medicine, Hebei University, Baoding, China.⁵¹³Department of Ophthalmology, Iran University of Medical Sciences, Tehran, Iran.⁵¹⁴Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, Warsaw, Poland.⁵¹⁵Department of Anatomy, Addis Ababa University, Addis Ababa, Ethiopia.⁵¹⁶Department of Nursing, Yasuj University of Medical Sciences, Yasuj, Iran.